Traditional Chinese medicine composition, and preparation and application thereof

ABSTRACT

A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a reissue of U.S. Pat. No. 9,999,630 issued on Jun.19, 2018, which claims priority to U.S. national stage ofPCT/CN2014/082102, filed on Jul. 11, 2014, which claims priority toChinese Patent Application No. 201310290968.8, filed on Jul. 11, 2013;Chinese patent application No. 201310384234.6, filed on Aug. 29, 2013;Chinese patent application No. 201410044675.6, filed on Jan. 30, 2014;and Chinese patent application No. 201410085152, filed on Mar. 10, 2014,the contents of which are each incorporated herein by reference in itsentirety.

FIELD OF THE INVENTION

The present invention relates to a traditional Chinese medicinecomposition and a preparation thereof, more particular to a traditionalChinese medicine composition for treating cardiovascular disease and apreparation thereof, especially a micro drop pill preparation. Also, thepresent invention relates to a method for preparing the traditionalChinese medicine and the preparation thereof Wherein, the method forpreparing the micro drop pill preparation can be used to prepare thedrop pills, coated drop pills and drop pill capsules with highdrug-loading capacity.

BACKGROUND OF THE INVENTION

With the improvement of living standards, worldwide population aging andyounger onset population, the patients with cerebral and cardiovasculardiseases are increased year by year. It has become the second largedisease that does harm to human health. Angina pectoris is a clinicalsyndrome which is characterized in chest pain and chest discomfort,caused by myocardial temporary ischemia and hypoxia. Coronary heartdisease (CHD) angina pectoris means the pectoris induced by myocardialischemia and hypoxia that is caused by coronary arteriosclerosis orspasm, accounting for about 90% of the patients with angina pectoris.

Now, the methods for treating angina pectoris are dominated by dilatingvessels, reducing blood viscosity and inhibiting platelets aggregationas well as anticoagulation. Traditionally, the chemicals include thenitrate, nitrite, β-receptor blocker and calcium antagonist. However,due to the stronger toxicity and side effect, these drugs are notsuitable to use for long time. In addition, most of them focus onsymptomatic treatment with no more effect on disease progress.Occasionally, symptoms occur after administrating the nitroglycerin, forexample the head pain, head throbbing, speed-up heartbeat and evensyncope (see New Pharmaceutics, 14^(th) edition, p 264). Recently, thenitroglycerin was reported to have problems of inducing severehypotension (see China Journal of Modern Medicine, 1997, 7 (4): 42,Shanxi Medicine Journal, 1996, 25(2) 315) and of being prone toproducing tolerance (see Nanfang Journal of Nursing, 1996, 3(5):7˜9).Hence, this hindered its application in clinic.

Although a lot of traditional Chinese medicines have been used fortreating angina pectoris, the pill, powder, ointment, Dan and decoctionhad become ancient history, which is seldom used by modern people. Now,there are common compound Salvia tablet and capsule commerciallyavailable. Because the production processes for the tablet and capsuleare outdated, the content of active ingredients is low with no qualitycontrol indices. Both are absorbed into blood via the gastrointestinaltract after oral administration. Due to the hepatic first pass effect,they have low bioavailability and slow absorption, and are not competentto the first aid for the patients with angina pectoris.

Drop pill is a traditional preparation for traditional Chinese medicine.It has the following merits: reduced volatility of drug, increased drugstability, high bioavailability, quickened onset of effect, prolongedaction in topical administration, shortened production cycle, dustpollution-free, and easily carried on.

However, the preparation method of traditional drop pill is to melt amedicine liquid and drop it into immiscible cooling medium to give thedrop pill. Because the drop pill is formed by the factors of downwardsgravity, surface tension of medicine liquid and internal stress, theunit drug loading capacity is small (usually, the drug loading capacityof API is about 25%) and the amount of matrix very large. This does notmeet the requirement of international market that the maximum daily doseof PEG matrix should not exceed 700 mg. Moreover, it is difficult toprepare the traditional drop pill with diameter of less than 2.5 mm, sothe patients have to take a lot of hard-to-swallow pills each time,which will not satisfy the fast-paced trend of modern life, and be proneto the problems of inaccurate dose. Thus, it is generally unacceptableby the international consumers. In addition, there are a number ofshortcomings in the preparation of traditional drop pill, e.g. the lowdropping rate, poor roundness and large variation on the pill weight andparticle size, as well as small unit drug loading capacity and largeamount of matrix (due to sufficient medium to ensure dropping effect).Because the cooling liquid has been used for solidifying the drop pill,the necessary step is needed in the sequent process to remove thecooling liquid, and the remaining cooling liquid may pose the problem ofresidual organic solvent. Besides, drying methods for the traditionaldrop pill have the defects of prolonged time, slow speed, uneven dryingand easily leading to evaporation of volatile oil and precipitation ofBorneol that is included in the products.

As a result of this, how to find a production process for preparingmicro drop pills, regular drop pills and drop pill capsules thatachieves high production rate, reduces amount of matrix and increasesdrug-loading capacity is an important subject in need of development andexploration of the modern formulation technique for drop pill.

Compound Salvia Drop Pill (CSDP) is a traditional Chinese medicinedeveloped by Tasly Pharmaceutical Co., Ltd, which is proven to have theeffects of activating blood by removing stasis as well as stopping painby regulating Qi, used for treating chest distress and angina pectoris.The main ingredients of CSDP include Salvia Miltiorrhiza, PanaxNotoginseng and Borneol. Its pharmacological effects include increasingcoronary blood flow, protecting ischemia myocardium by strengtheninghypoxia tolerance, anti-platelet aggregation, preventing thrombosis andimproving microcirculation etc. Although the preparation of CSDP isknown as a very mature technique in the prior art, there are still a lotof problems faced during preparation process, e.g. large amount ofmatrix and small drug-loading capacity.

CONTENT OF THE INVENTION

The objective of present invention is to provide a traditional Chinesemedicine composition for treating acute myocardial infarction and acutemyocardial ischemia. Said composition is composed of following materialsby weight percentage: 50.0%˜99.9% of Salvia Miltiorrhiza and PanaxNotoginseng extract and 0.1%˜50.0% of borneol. Wherein, the SalviaMiltiorrhiza and Panax Notoginseng extract comprises followingingredients by weight parts:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1 :Ginsenoside Rg1:Ginsenoside Re:GinsenosideRb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA=(2˜6):(0.5˜2):(1˜3):(0.2˜1):(0.2˜1):(0.5˜2):(0.5˜2):(0.2˜1):(1˜4):(0.1˜0.5):(1˜4):(0.1˜1):(0.01˜0.05):(0.05˜0.1):(0.02˜0.1):(0.1˜0.5).

In an embodiment of this invention, said composition may be preparedinto various kinds of preparations, such as injections, tablets,capsules, drop pills and micro drop pills, preferably the micro droppill. Said micro drop pill means a smaller-sized drop pill than thetraditional drop pill. In particular, said micro drop pill has theparticle size of 0.2 mm˜4 mm, especially 0.2 mm˜2 mm, most preferably 1mm˜2 mm.

Another objective of present invention is to provide a compound Salviamicro drop pill (CSMDP). In said micro drop pill, the weight ratio ofmedicine to matrix is 1:5˜5:1, and particle size 0.2 mm˜4 mm. Thepreparation method for preparing said micro drop pill comprises thesteps as follows:

Material melting step: heating and melting medicine and a drop pillmatrix to obtain a molten medicine liquid;

Dropping step: delivering the molten medicine liquid to a dripper, andacquiring medicine drops of the molten medicine liquid by means ofvibration dropping; and

Condensation step: cooling the medicine drops with cooling gas to obtainmicro drop pills.

In particular, the present invention comprises technical solutions asfollows:

1. A traditional Chinese medicine composition composed of the followingmaterials by weight percentage: 50.0%˜99.9% of Salvia Miltiorrhiza andPanax Notoginseng extract and 0.1%˜50.0% of borneol, wherein the SalviaMiltiorrhiza and Panax Notoginseng extract comprises followingingredients by weight percentage:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1 :Ginsenoside Rg1:Ginsenoside Re:GinsenosideRb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA-(2˜6):(0.5˜2):(1˜3):(0.2˜1):(0.2˜1):(0.5˜2):(0.5˜2):(0.2˜1):(1˜4):(0.1˜0.5):(1˜4):(0.1˜1):(0.01˜0.05):(0.05˜0.1):(0.02˜0.1):(0.1˜0.5).

2. The traditional Chinese medicine composition according to 1^(st)paragraph, wherein said composition is composed of following materialsby weight percentage: 75.0%˜99.9% of Salvia Miltiorrhiza and PanaxNotoginseng extract and 0.1%˜25.0% of borneol.

3. The traditional Chinese medicine composition according to 1^(st)paragraph, wherein said composition is composed of the followingmaterials by weight percentage: 90.0%˜99.9% of Salvia Miltiorrhiza andPanax Notoginseng extract and 0.1%˜10.0% of borneol.

4. The traditional Chinese medicine composition according to any one of1^(st)˜3^(rd) paragraphs, wherein the Salvia Miltiorrhiza and PanaxNotoginseng extract comprises following ingredients by weight parts:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1 :Ginsenoside Rg1:Ginsenoside Re:GinsenosideRb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA=(3˜4):(0.9˜1.2):(1.4˜2.0):(0.5˜0.7):(0.5˜0.9):(1˜1.6):(0.7˜1.2):(0.5˜0.9):(1.8˜2.8):(0.2˜0.4):(1.7˜2.2):(0.2˜0.6):(0.03˜0.04):(0.07˜0.08):(0.05˜0.06):(0.26˜0.28).

5. The traditional Chinese medicine composition according to 4^(th)paragraph, wherein the Salvia Miltiorrhiza and Panax Notoginseng extractcomprises following ingredients by weight parts:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1:Ginsenoside Rg1:Ginsenoside Re:GinsenosideRb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA=3.6:1.1:1.7:0.6:0.7:1.3:0.9:0.7:2.4:0.3:1.8:0.4:0.03:0.07:0.06:0.27.

6. The traditional Chinese medicine composition according to any one of1^(st)˜3^(rd) paragraphs, wherein the Salvia Miltiorrhiza and PanaxNotoginseng extract is prepared with following crude medicine by weightparts: Salvia Miltiorrhiza 75˜90 parts and Panax Notoginseng 10˜25parts.

7. The traditional Chinese medicine composition according to 6^(th)paragraph, wherein the Salvia Miltiorrhiza and Panax Notoginseng extractis prepared with following crude medicine by weight parts: SalviaMiltiorrhiza 82˜84 parts, Panax Notoginseng 16˜17 parts.

8. A pharmaceutical preparation comprising the traditional Chinesemedicine composition according to any one of s1^(st)˜7^(th) paragraphsand pharmaceutically acceptable carriers.

9. The pharmaceutical preparation according to 8^(th) paragraph, whereinsaid preparation is in a dosage form of drop pill or micro drop pill,preferably the micro drop pill, wherein said micro drop pill is preparedwith the traditional Chinese medicine composition and the drop pillmatrix in a ratio of 1:5˜5:1 by weight.

10. A compound Salvia micro drop pill, wherein said micro drop pill isprepared with the traditional Chinese medicine composition according toany one of 1^(st)˜7^(th) paragraphs and drop pill matrix in a ratio of1:5˜5:1 by weight.

11. The preparation method for the micro drop pill according to 10^(th)paragraph, comprising following steps:

(1) Material melting step: charging said medicine and matrix into ahomogenizer, mixing homogenously at 1000˜5000 rpm for 1˜200 min, meltinghomogenously at 3000˜10000 rpm for 1˜100 min; during the meltingprocess, the temperature is kept at 60˜100° C. to obtain the moltenmedicine liquid; said ratio of medicine to the micro drop pill matrix is1:5˜5:1 by weight;

(2) Dropping step: delivering the molten medicine liquid to a dripper,and acquiring medicine drops from the dripper by means of vibrationdropping at a vibration frequency of 2˜2000 Hz under a dropping pressureof 0.5˜4.0 Bar, with an acceleration at 1˜20 G; the temperature of thedripper is at 70˜300° C.; the dropping rate is matched with the meltingrate in step (1); and

(3) Condensation step: cooling the medicine drops with cooling gasrapidly to solidify and obtaining the solid drop pill having a particlesize of 0.2 mm˜4.0 mm; the temperature of the cooling gas is 0° C. orlower.

12. The preparation method according to 11^(th) paragraph, wherein instep (1), said drop pill matrix includes one or more of PEG, sorbitol,xylitol, lactitol, maltose, starch, methylcellulose, sodiumcarboxymethyl cellulose, hydroxypropyl methylcellulose (HPMC), Arabicgum, alginate, dextrin, cyclodextrin, agar and lactose, preferably thesolid PEG, e.g. PEG-1000, PEG-2000, PEG-3000, PEG-4000, PEG-5000,PEG-6000, PEG-7000 and PEG-8000, more preferably one or more of thePEG-1000, PEG-2000, PEG-3000, PEG-4000, PEG-6000, PEG-8000, mostpreferably the PEG-6000, PEG-4000, or the combination of PEG-4000 andPEG-6000.

13. The preparation method according to 11^(th) or 12^(th) paragraph,wherein said method comprises the following steps:

(1) Material melting step: charging the medicine and matrix into ahomogenizer, mixing homogenously at 1000˜5000 rpm, melting homogenouslyat 3000˜10000 rpm for 20˜80 min; during the melting process, thetemperature is kept at 80˜100° C. to obtain the molten medicine liquid;the ratio of the medicine to the micro drop pill matrix is 1:3˜3:1 byweight;

(2) Dropping step: delivering the molten medicine liquid to a dripper,and acquiring medicine drops from the dripper by means of vibrationdropping at a vibration frequency of 20˜300 Hz under a dropping pressureof 0.5˜4.0 Bar, with an acceleration at 1˜15 G; the temperature of thedripper is at 70˜200° C.; the dropping rate is matched with the meltingrate in step (1); and

(3) Condensation step: cooling the medicine drops with cooling gasrapidly to solidify and obtaining solid drop pill having a particle sizeof 0.2 mm˜4.0 mm; the temperature of the cooling gas is 0° C. or lower.

14. The preparation method according to 12^(th) paragraph, wherein instep (1), the ratio of the medicine to the drop pill matrix is 1:3˜3:1by weight, mixing homogeneously 3000˜5000 rpm for 10˜60 min and meltinghomogeneously at 4000˜9000 rpm for 5˜30 min, during the melting process,the temperature is kept at 70˜90° C.; preferably, the ratio of themedicine to the matrix is 1:(1˜3) by weight, mixing homogeneously3000˜4000 rpm for 10˜30 min and melting homogeneously at 4000˜6000 rpmfor 6˜30 min, and during the melting process the temperature is kept at75˜85° C.

15. The preparation method according to 12^(th) paragraph, wherein instep (2), the temperature of the dripper is at 70˜100° C., preferably at75˜85° C.; the vibration frequency is at 50˜300 Hz, preferably at100˜200 Hz, more preferably at 90˜200 Hz, more preferably at 130˜140 Hz,most preferably at 137 Hz; the acceleration is at 3.5˜4.5 G, preferablyat 4.0 G; the dropping pressure is at 1.0˜3.0 Bar, preferably at 1.8Bar; and the dropping rate is 10˜40 kg/h, preferably 12˜30 kg/h, furtherpreferably 15˜25 kg/h.

16. The preparation according to 12^(th) paragraph, wherein in step (3),the cooling gas is selected from air, nitrogen and inert gas; thetemperature of the cooling gas is 0˜−150° C., preferably −60˜−140° C.,more preferably −80˜−120° C.; the particle size is 1.0 mm˜2.0 mm.

17. The preparation method according to any one of 11^(th)˜16^(th)paragraphs, wherein said method may additionally comprise step (4) ofdrying: fluidized-bed drying to perform drying at −20˜100° C.,preferably −20˜90° C., for 1˜4 hours to obtain a blank drop pill.

18. The preparation method according to 17^(th) paragraph, wherein alow-temperature drop pill from step (3) is dried with fluidized bed at40˜150° C., preferably 40˜60° C. for 1˜4 hours, preferably 1˜3 hours,most preferably 2 hours, to obtain the blank pill.

19. The preparation method according to 18^(th) paragraph, wherein instep (4), gradient-rising temperature drying method is used as follows:fluidizing at −20˜30° C., drying at 15˜35° C. for 10˜120 min, drying at35˜55° C. for 10˜60 min, drying at 55˜100° C. for 0˜60 min; preferablyfluidizing at 0˜20° C., drying at 25° C. for 60 min, drying at 45° C.for 30 min, drying at 55° C. for 0˜30 min.

20. The preparation method according to any one of 11^(th)˜19^(th)paragraphs, wherein said method may additionally comprise step (5) ofcoating: coating the blank pill obtained from step (4) in a state offluidization under 30˜65° C.; wherein the concentration of coatingliquid is at 5˜25 wt %, preferably 18˜20 wt %; coating material isselected from shellac, CAP (cellulose acetate phthalate), methylacrylate, methyl methacrylate or opadry; the ratio of the coatingmaterial to the blank drop pill is 1:50˜1:10, preferably 1:50˜1:25.

21. The preparation method according to any one of 11^(th)˜20^(th)paragraphs, wherein said method may additionally comprise a premixingstep before step (1): adding medicine powder or extract with water,stirring for 10 min or longer at 30˜80° C. to obtain a premixed medicinematerial.

22. Use of the traditional Chinese medicine composition according to1^(st)˜7^(th) paragraphs in preparation of a medicament for treatingacute myocardial infarction and acute myocardial ischemia.

DESCRIPTION OF THE DRAWINGS

FIG. 1 was the high resolution mass spectrum of salvianolic acid T, A:(R)-salvianolic acid T; B: (S)-salvianolic acid T.

FIG. 2 was the ¹H-NMR spectrum of salvianolic acid T (500 MHz, DMSO), A:(R)-salvianolic acid T; B: (S)-salvianolic acid T.

FIG. 3 was the ¹³C-NMR spectrum of salvianolic acid T (125 MHz, DMSO),A: (R)-salvianolic acid T; B: (S)-salvianolic acid T.

FIG. 4 was the DEPT spectrum of salvianolic acid T, A: (R)-salvianolicacid T; B: (S)-salvianolic acid T.

FIG. 5 was the COSY spectrum of salvianolic acid T, A: (R)-salvianolicacid T; B: (S)-salvianolic acid T.

FIG. 6 was the ROESY spectrum of salvianolic acid T, A: (R)-salvianolicacid T; B: (S)-salvianolic acid T.

FIG. 7 was the HSQC spectrum of salvianolic acid T, A: (R)-salvianolicacid T; B: (S)-salvianolic acid T.

FIG. 8 was the HMBC spectrum of salvianolic acid T, A: (R)-salvianolicacid T; B: (S)-salvianolic acid T.

FIG. 9 was the CD spectrum of salvianolic acid T, A: (R)-salvianolicacid T; B: (S)-salvianolic acid T.

FIG. 10 was the comparison of CD spectrum and ECD simulated spectrum, A:(R)-salvianolic acid T; B: (S)-salvianolic acid T.

FIG. 11 was the chromatogram of Salvianolic acids and tanshinones(detective wavelength at 281 nm).

FIG. 12 was the chromatogram of saponines.

DETAILED EMBODIMENTS

In an embodiment of this invention, the present invention is to providea traditional Chinese medicine composition. Said composition is composedof following materials by weight percentage: 50.0%˜99.9% of SalviaMiltiorrhiza and Panax Notoginseng extract and 0.1%˜50.0% of borneol.Wherein, the Salvia Miltiorrhiza and Panax Notoginseng extract comprisesfollowing ingredients by weight percentage:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1 :Ginsenoside Rg1: Ginsenoside Re:Ginsenoside Rb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA-(2˜6):(0.5˜2):(1˜3):(0.2˜1):(0.2˜1):(0.5˜2):(0.5˜2):(0.2˜1):(1˜4):(0.1˜0.5):(1˜4):(0.1˜1):(0.01˜0.05):(0.05˜0.1):(0.02˜0.1):(0.1˜0.5).

Preferably, said composition is composed of following materials byweight percentage: 75.0%˜99.9% of Salvia Miltiorrhiza and PanaxNotoginseng extract and 0.1%˜25.0% of borneol.

More preferably, said composition is composed of following materials byweight percentage: 90.0%˜99.9% of Salvia Miltiorrhiza and PanaxNotoginseng extract and 0.1%˜10.0% of borneol.

Preferably, the Salvia Miltiorrhiza and Panax Notoginseng extractcomprises following ingredients by weight parts:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1:Ginsenoside Rg1:Ginsenoside Re:Ginsenoside Rb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA=(3˜4):(0.9˜1.2):(1.4˜2.0):(0.5˜0.7):(0.5˜0.9):(1˜1.6):(0.7˜1.2):(0.5˜0.9):(1.8˜2.8):(0.2˜0.4):(1.7˜2.2):(0.2˜0.6):(0.03˜0.04):(0.07˜0.08):(0.05˜0.06):(0.26˜0.28).

More preferably, the Salvia Miltiorrhiza and Panax Notoginseng extractcomprises following ingredients by weight parts:

Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1:Ginsenoside Rg1:Ginsenoside Re:Ginsenoside Rb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinoneIIA=3.6:1.1:1.7:0.6:0.7:1.3:0.9:0.7:2.4:0.3:1.8:0.4:0.03:0.07:0.06:0.27.

In an embodiment of this invention, aforesaid traditional Chinesemedicine composition is prepared by extracting Salvia Miltiorrhiza andPanax Notoginseng to give the extract, adding the borneol into theextract and mixing to have the product.

Preferably, the traditional Chinese medicine is prepared by thefollowing method:

(1) Decocting Salvia Miltiorrhiza and Panax Notoginseng with water underalkaline conditions to give the decoction, filtering the decoction,concentrating and precipitating the filtrate with alcohol to get thesupernatant, filtering the supernatant, recovering the alcohol to givethe extract (or further drying the extract), namely the SalviaMiltiorrhiza and Panax Notoginseng extract;

(2) Adding the extract of above step with borneol and mixing uniformly.

Wherein, Salvia Miltiorrhiza and Panax Notoginseng may be decocted withwater under alkaline condition either alone, or in combination.

Preferably, the Salvia Miltiorrhiza and Panax Notoginseng extract isprepared by following method:

(1) Salvia Miltiorrhiza and Panax Notoginseng are decocted with alkalinewater solution for 1˜3 times, 1˜3 hours each time and filtered to getthe filtrate I for later use;

(2) Resultant residue is decocted with water for 1˜3 times, 1˜3 hourseach time, filtered to get the filtrate II for later use;

(3) The filtrate I and filtrate II are combined and concentrated to havethe concentrated liquid, which is precipitated with alcohol and allowedto stand still to get the supernatant; the supernatant is taken,filtered, the alcohol was recovered and concentrated to give the extract(or drying the extract), namely the Salvia Miltiorrhiza and PanaxNotoginseng extract.

Wherein, said alkaline water solution includes, but not limited to, oneor more of sodium bicarbonate, sodium carbonate, sodium hydrogenphosphate, sodium dihydrogen phosphate, sodium hydroxide, potassiumhydroxide and magnesium hydroxide with the pH value of 7.5˜9.0; theconcentration of the alkaline water solution is 1˜4.5 wt %, preferably2.25˜3 wt %, ensuring that Danshensu and salvianolic acid T can beextracted totally.

In step (3), 50˜100% (v/v) ethanol, most preferably 95% ethanol, wasadded to perform ethanol-precipitation, the final content of ethanolpreferably 60˜75% (v/v).

More preferably, the Salvia Miltiorrhiza and Panax Notoginseng extractis prepared by the following method:

(1) Salvia Miltiorrhiza is cut to 5 cm or smaller in length, preferably1˜2 cm, and Panax Notoginseng is ground into particles of 1 cm; sodiumbicarbonate accounting for 2.25˜3 wt % of total crude medicine isweighed and charged into an extracting tank together with weighed SalviaMiltiorrhiza and Panax Notoginseng; in each tank, 5 times of water isadded to heat and keep boiling for 2 h±20 min and filtered;

(2) Resultant residue is extracted for 2^(nd) time by adding 4 times ofwater to heat and keep boiling for 1 h±15 min, filtered and the residuewas removed;

(3) Afore-obtained extraction liquid is concentrated under reducedpressure to a relative density of 1.16˜1.20 (80±5° C.) or correspondingsugar degree of 48˜52% to give the concentrated liquid; the concentratedliquid is delivered to a alcohol precipitating tank, into which anappropriate amount of alcohol is added to make the final content ofalcohol at 65˜70% and allowed to stand still for 12˜24 hours untilcomplete precipitation; the supernatant is taken with the depositremoved; the supernatant is concentrated or dried to give the extract,namely the Salvia Miltiorrhiza and Panax Notoginseng extract.

Wherein, in step (1), 5 times of water means that the water is 5 timesof total crude medicine in weight. Similarly, in step (2), 4 times ofwater means that the water is 4 times of total residue in weight.

In an embodiment of this invention, said traditional Chinese medicinecomposition is prepared by following crude medicine by weight parts:Salvia Miltiorrhiza 75˜90 parts, Panax Notoginseng 10˜25 parts andBorneol 0.1˜4 parts.

Preferably, said traditional Chinese medicine composition is prepared byfollowing crude medicine by weight parts: Salvia Miltiorrhiza 80˜86parts, Panax Notoginseng 15˜18 parts and Borneol 0.2˜2 parts.

Most preferably, said traditional Chinese medicine composition isprepared by following crude medicine by weight parts: SalviaMiltiorrhiza 82˜84 parts, Panax Notoginseng 16˜17 parts and Borneol0.4˜1.2 parts.

In an embodiment of this invention, said traditional Chinese medicinecomposition is either extract or powder.

In an embodiment of this invention, during the process for detecting thebioactive ingredients of Salvia Miltiorrhiza and Panax Notoginsengextract, it is first time to discover bioactive ingredients in aforesaidratio by weight, and first time to separate and obtain new compound ofsalvianolic acid T.

In an embodiment of this invention, the structure of new compound ofsalvianolic acid was identified in its physicochemical properties, highresolution mass spectrum (QFT-ESI), electrospray ionization massspectrum (ESI-MS), ¹H-NMR, ¹³C-NMR, DEPT, COSY, HMBC, HMQC and CDspectra (FIGS. 1˜10).

The structure of the new compound of salvianolic acid is represented bythe general formula (I) as follows,

¹H-NMR shows 1 signal of methenyl proton attached to oxygen at δ 4.93(1H, dd, 8.0, 4.5 Hz); 11 signals of aromatic proton at δ 6.85 (1H, d,8.5 Hz), δ 7.31 (1H, d, 8.5 Hz), δ 7.41 (1H, d, 15.5 Hz), δ 6.27 (1H, d,15.5 Hz), δ 6.62 (1H, s), δ 6.63 (1H, d, 8.0 Hz), δ 6.47 (1H, d, 8.0Hz), δ 6.44 (1H, d, 2.0 Hz), δ 6.55 (1H, d, 8.5 Hz), δ 6.43 (1H, dd,8.5, 2.0 Hz), δ 7.69 (1H, s); 2 signals of aliphatic proton at δ 2.89(2H, ddd, 14.0, 8.0, 4.5 Hz).

Carbon-13 nuclear magnetic resonance ¹³C-NMR spectrum shows 27 carbonsignals, including 1 aliphatic carbon signal at δ 36.0, 1 signal ofmethenyl carbon attached to oxygen at δ 72.8, 3 signals of carbonylcarbon at δ 166.0, δ 170.6, δ 168.4 and 22 signals of double-bond carbonat δ 123.7, δ 126.4, δ 142.9, δ 147.7, δ 115.0, δ 118.4, δ 143.7, δ113.9, δ 127.1, δ 116.5, δ 143.9, δ 144.8, δ 115.5, δ 120.0, δ 126.0, δ117.3, δ 144.8, δ 147.2, δ 115.3, δ 122.9, δ 141.1, δ 123.4.

In an embodiment of this invention, said compound of the presentinvention has 2 isomers with optical rotation respectively at −157.5°and 196.6°. Compound with C-8′ absolute configuration set asS/R-configuration is obtained through molecular optimum design andcalculated by BPV86 method having TD-SCF with (2d, p) basis sets to readcomparison between result and experimental CD spectrum of the compound.It is inferred by the substantially matched CD spectra that the absoluteconfiguration of C-8′ in 2 isomers of the compound of the presentinvention are S configuration and R configuration (see FIG. 10). Thespectrum by HMBC of the compound in the present invention is presentedas follows:

Said salvianolic acid T is prepared by the following method:

a) extraction: extracting Salviae Miltiorrhizae crude drug or a mixtureof Salviae Miltiorrhizae and other crude drugs with water and filtering,concentrating the filtrate, adding alcohol to precipitate and obtain asupernatant, then concentrating the supernatant to obtain an extract;

b) separation: dissolving the extract of the step a) in water, applyingon the macroporous absorbent resin, eluting the resin with acidicsolution to remove the impurities and then eluting with ethanol toobtain an ethanol eluent, concentrating the ethanol eluent to obtain anextract;

c) purification: purifying the extract of the step b) with high-pressurepreparative LC; stationary phase is C18 reversed-phase silica column;mobile phase is acetonitrile-water-formic acid by isocratic elution orgradient elution method with detective wavelength at 280 nm; HPLC isused to monitor the process of elution to collect the eluent containingthe salvianolic acid T; after being concentrated, the salvianolic acid Tis obtained.

In an embodiment of this invention, the preparation of said traditionalChinese medicine composition is provided, and said preparation of thepresent invention comprises the traditional Chinese medicine compositionand one or more kinds of pharmaceutically acceptable carriers. Saidtraditional Chinese medicine composition may account for 0.1˜99.9 wt %of said preparation, and the balanced is pharmaceutically acceptablecarrier.

In an embodiment of this invention, the composition is prepared in theform of unit dosage and said unit dosage refers to individualpreparation, e.g. each tablet of tablets, each capsule of capsules, eachbottle of oral solutions and each bag of granules etc, and is preparedby any one of methods known in pharmaceutical field. All methods includethe step of combining traditional Chinese medicine composition with thecarriers. Said carriers are composed of one or more kinds of adjuvants.In general speaking, said preparation is prepared by the followingmethod: uniformly and tightly combining said traditional Chinesemedicine composition with liquid carrier, finely ground solid carrier ormixture of both to give the outcome, and, if necessary, preparing theoutcome into desirable dosage form. Usually, standard pharmaceuticaltechniques may be used, which includes combining said traditionalChinese medicine composition with pharmaceutically acceptable carrier toprepare them into the pharmaceutical dosage form of the presentinvention. These methods include steps of mixing, granulating andtableting. Known to the person skilled in the prior art, the form andcharacteristic of said pharmaceutically acceptable carrier or dilutingagent depend on the quantity of bio-active ingredients to be mixed,administration route of preparation and other known factors.

In an embodiment of this invention, said composition can be prepared inany pharmaceutically acceptable dosage form, including the tablet suchas sugar-coated tablet, film-coated tablet and enteric-coated tablet,the capsule such as soft capsule and hard capsule, the oral liquidsolution, the buccal tablet, the granules, the instant powder, the pill,the pulvis, the paste such as ointment and paster, the Dan, thesuspension, the powder, the solution, the injection, the suppository,the cream, the ointment, the plaster, the spray, the drop, the drop pilland the patch, preferably the orally-administrated dosage form, such asthe capsule, the tablet, the oral solution, the granule, the pill, thepowder, the Dan and the ointment etc.

In an embodiment of this invention, said orally-administrated dosageform includes carriers such as the adhesive, filling agent, diluent,tableting agent, lubricant, disintegrating agent, colorant agent,flavoring agent, wetting agent. If necessary, the tablet may be coated.

In an embodiment of this invention, said filling agents includecellulose, mannitol, lactose and other analogous filling agent. Suitabledisintegrating agents include starch, polyvinylpyrrolidone (PVP) andstarch derivative (e.g. sodium hydroxyethyl starch). Suitable lubricantsinclude magnesium stearate. Suitable wetting agents include sodiumdodecyl sulfate.

In an embodiment of this invention, oral solid preparations of saidcomposition can be prepared by blending repeatedly to make thebio-active ingredients (API) distributed uniformly into a large numberof filling agent.

In an embodiment of this invention, oral liquid preparations are indosage form of either water-soluble or oil-soluble suspension, solution,emulsion, syrup or elixir, or drying powder that is always reconstitutedwith water or other suitable solvent before clinical use. This liquidpreparation may contain conventional excipients, for example suspendingagent, e.g. sorbitol, syrup, methylcellulose, gelatin, hydroxy ethylcellulose, carboxy methyl cellulose, aluminum stearate gel orhydrogenated edible fat; emulsifying-agent, e.g lecithin, sorbitanmonoleate or arabic gum; non-aqueous excipient (including edible oil)e.g. almond oil, fractionated coconut oil, oil ester such as glyceride;propylene glycol or ethanol; as well as preservative e.g. methylparaben,nipasol, sorbic acid. If necessary, conventional flavoring agent orcolorant agent can be included.

In an embodiment of this invention, said injection contains bio-activecomponents and aseptic excipients. To the person skilled in the priorart, said bio-active component is dissolved or suspended in the liquidaccording to the type and concentration of excipients. Generally,solution is prepared by dissolving the bio-active components in theexcipients, sterilizing, loading into a suitable vial or ampoule andsealing. Some pharmaceutically acceptable adjuvant, e.g. localanaesthetic, preservative and buffering agent can be added as required.In order to improve its stability, before loaded into the vial, thiscomposition of the present invention can be frozen and treated in vacuumto remove water.

In an embodiment of this invention, said traditional Chinese medicinecomposition can be prepared by optionally adding pharmaceuticallyacceptable excipients. Said excipients are selected from: mannitol,sorbitol; sodium thiosulfate; cysteine hydrochloride, mercaptoaceticacid, methionine, Vitamin C; EDTA disodium, EDTA calcium disodium salt;monovalent alkali carbonate, acetate, phosphate or its aqueous solution;hydrochloride, acetic acid, sulfuric acid, phosphoric acid; amino acid;sodium chloride, potassium chloride, sodium lactate; xylitol; maltose,glucose, fructose, dextran; glycine; starch, sucrose, lactose, mannitol;silicon derivative; cellulose and its derivatives; alginate; gelatin;PVP, glycerol; Tween-80, agar gel; calcium carbonate, calciumbicarbonate; surfactant; PEG; cyclodextrin; phospholipids; Kaolin;talcum powder, calcium stearate, magnesium stearate; and the like.

Preferably, said composition is prepared into the drop pill, morepreferably the micro drop pill.

In an embodiment of this invention, a compound Salvia micro drop pill(CSMDP) is provided and said CSMDP is prepared with traditional Chinesemedicine composition and the micro drop pill matrix in a ratio of1:5˜5:1 by weight, preferably prepared with traditional Chinese medicinecomposition and the micro drop pill matrix in a ratio of 1:3˜3:1 byweight, most preferably in a ratio of 1:(1˜3).

In an embodiment of this invention, the preparation method for preparingCSMDP comprises following steps:

(1) Material melting step: charging the medicine and drop pill matrixinto a homogenizer, mixing homogenously at 1000˜5000 rpm for 1˜200 min,melting homogenously at 3000˜10000 rpm for 1˜100 min; during the meltingprocess, the temperature is kept at 60˜100° C. to obtain the moltenmedicine liquid; the ratio of the medicine to the micro drop pill matrixis 1:5˜5:1 by weight;

(2) Dropping step: delivering the molten medicine liquid to a dripper,and acquiring medicine drops from the dripper by means of vibrationdropping at a vibration frequency of 2˜2000 Hz under a dropping pressureof 0.5˜4.0 Bar, with an acceleration at 1˜20 G; and the temperature ofthe dripper is at 70° C.˜300° C.; the dropping rate is matched with themelting rate in step (1); and

(3) Condensation step: cooling the medicine drops with cooling gasrapidly to solidify and obtaining solid drop pill having a particle sizeof 0.2 mm˜4.0 mm; the temperature of the cooling gas is 0° C. or lower.

Preferably, the preparation method for preparing CSMDP comprisesfollowing steps:

(1) Material melting step: charging the medicine and matrix into ahomogenizer, mixing homogenously at 1000˜5000 rpm for 1˜200 min, meltinghomogenously at 3000˜10000 rpm for 1˜100 min; during the meltingprocess, the temperature is kept at 60˜100° C. to obtain the moltenmedicine liquid; the ratio of medicine to the micro drop pill matrix is1:3˜3:1 by weight;

(2) Dropping step: delivering the molten medicine liquid to a dripper,and acquiring medicine drops from the dripper by means of vibrationdropping at a vibration frequency of 20˜300 Hz under a dropping pressureof 0.5˜4.0 Bar, with an acceleration at 1˜15 G; the temperature of thedripper is at 70° C.˜200° C.; the dropping rate is matched with themelting rate in step (1); and

(3) Condensation step: cooling the medicine drops with cooling gasrapidly to solidify and obtaining the solid drop pill having a particlea size of 0.2 mm˜4.0 mm; the temperature of the cooling gas is 0° C. orlower.

Wherein, in step (1), said drop pill matrix includes one or more of PEG,sorbitol, xylitol, lactitol, maltose, starch, methylcellulose, sodiumcarboxymethyl cellulose, hydroxypropyl methylcellulose (HPMC), Arabicgum, alginate, dextrin, cyclodextrin and agar, preferably the solid PEG,e.g. PEG-1000, PEG-2000, PEG-3000, PEG-4000, PEG-5000, PEG-6000,PEG-7000 and PEG-8000, more preferably one or more of the PEG-1000,PEG-2000, PEG-3000, PEG-4000, PEG-6000, PEG-8000, most preferably thePEG-6000, PEG-4000, or the combination of PEG-4000 and

PEG-6000. In step (1), homogenization may enhance content uniformity,and RSD is improved from previous 10% to 7%.

Preferably, in step (1), said ratio of medicine to drop pill matrix is1:3˜3:1 by weight, mixing homogeneously 3000˜5000 rpm for 10˜60 min andmelting homogeneously at 4000˜9000 rpm for 5˜30 min, and during themelting process the temperature is kept at 70˜90° C.; most preferably,said ratio of medicine to the matrix is 1:(1˜3) by weight, mixinghomogeneously 3000˜4000 rpm for 10˜30 min and melting homogeneously at4000˜6000 rpm for 6˜30 min, and during the melting process thetemperature is kept at 75˜85° C.

In step (2), preferably, said temperature of dripper is at 70˜100° C.,preferably 75˜85° C.; the vibration frequency at 50˜300 Hz, preferably100˜200 Hz, more preferably 90˜200 Hz, more preferably 130˜140 Hz, mostpreferably 137 Hz; acceleration at 3.5˜4.5 G preferably 4.0 G; droppingpressure at 1.0˜3.0 Bar, preferably 1.8 Bar; dropping rate is 10˜14Kg/h, preferably 12˜30 Kg/h, further preferably 15˜25 Kg/h.

In step (3), said condensation by cooling gas means that the fallingdrops are cooled by using low-temperature condensate trap to makesolidification. Said temperature of cooling gas is 0° C. or lower,preferably at 0˜−150° C., further preferably −60° C.˜−140° C., mostpreferably −80° C.˜−120° C.; said cooling gas is air, nitrogen or inertgas; said particle size of micro drop pill is 1.0 mm˜2.0 mm.

Further, said method may additionally comprise step (4) of drying step:fluidized-bed drying equipment is preferred at −20˜100° C., preferablydrying at −20˜90° C. for 1˜4 hours to obtain the blank drop pill.Especially, fluidized-bed drying the low-temperature drop pill from step(3) is performed at 40˜150° C., preferably 40˜60° C. for 1˜4 hours,preferably 1˜3 hours, most preferably 2 hours, to obtain the blank droppill.

In step (4), gradient-rising temperature drying method is preferred,including steps of: fluidizing at −20˜30° C., drying at 15˜35° C. for10˜120 min, drying at 35˜55° C. for 10˜60 min, drying at 55˜100° C. for0˜60 min; preferably fluidizing at 0˜20° C., drying at 25° C. for 60min, drying at 45° C. for 30 min, drying at 55° C. for 0˜30 min. In thisstep, the drop pills are in state of fluidization, not only solving theproblems of drop pill adhesion, but also enhancing the efficiency andproductivity up to 30 kg/h.

In step (4), by screening through a large number of the drying methods,the inventors found that: in step (3), the blank pill is dried by one offollowing drying methods: the low-humidity airing method, coating potdrying method, vacuum oven drying method, hot-air blasting dryingmethod, track microwave heating drying method, fluidization dryingcoating method. In terms of yield and productivity, the coating potdrying method, track microwave heating drying method and fluidizationdrying coating method are preferred. In terms of the industrialization,the fluidization bed drying method is preferred, and the fluidizationdrying coating method is more preferred. Advantages and disadvantages ofvarious drying methods are shown in Table 1.

TABLE 1 Drying No. mode Advantages Disadvantages 1 Low- High yield. Theyield (1) Stringent requirement for drying temper- is usually about 95%environment, demanding the air- ature without consideration circulatedclean workshop with the airing of dropping factors, relative humidityless than 30%, temperature 20° C. or more; (2) Prolonged drying period,48 hours required when thickness of drop pill is up to about 2 cm; (3)Large area workshop occupied; (4) Turning regularly; (5) Exposing forlong time, prone to pollution. 2 Coating (1) High yield. The (1)Demanding the inlet air having pot yield is usually about low humidity,generally not more than drying 95% without 5 g/kg; consideration of (2)Low drying efficiency at least 6 h/ dropping factors; batch; (2) Dryingand (3) Customerized device; coating can be (4) Easily resulting inproduct achieved rejection due to the adhersion of drop simutaneously.pills. 3 Vacuum None (1) Low drying efficiency, demanding oven longtimelow-temperature vacuum drying drying, at least 30 hours/batch; (2)Low-productivity device, the productivity of oven per square meter isdifficult to exceed 0.2 kg/h; (3) Easily resulting in adhesion anddeformation of drop pill, which is not round in appearance. 4 Hot-airNone (1) Low drying efficiency, demanding blasting low-temperaturedrying for long time, drying at least 40 hours/batch; (2)Low-productivity device, the productivity of oven per square meter isdifficult to exceed 0.1 kg/h; (3) Easily resulting in adhesion anddeformation of drop pill, which is not round in appearance; (4) Dryingworkshop with relative humidity of less than 30%. 5 Track High yield,reaching (1) Difficult to control the drying micro- 20 Kg/h. process,easily resulting in adhesion wave and deformation of drop pill, which isheating not round in appearance, or product drying rejection due tocharring; (2) Relative humidity less than 30% in drying workshop; (3)Unable to solve residual microwave in product. 6 Fluid- (1) High yield,Inlet air humidity should be ization reaching 30 kg/h; controlled,generally not more than driying (2) Drying and 7.5 g/kg. coating coatingdrying simultaneously; (3) Round drop pill in appearance; (4) Highyield. The yield is usually over 98% without consideration of droppingfactors; (5) Easily controlled during drying, real- time displaying thewater content.

Further, said preparation method for micro drop pill may additionallycomprise step (5) of coating: coating the blank pill obtained from step(4) in a state of fluidization at 30˜65° C.; the concentration ofcoating liquid is at 5˜25 wt %, preferably 18˜20 wt %; the coatingmaterial is selected from shellac, CAP (cellulose acetate phthalate),methyl acrylate, methyl methacrylate or opadry; the ratio of coatingmaterial to the blank pill is 1:50˜1:10, preferably 1:50˜1:25.

In order to better implement the preparation method for micro drop pill,preferably, said method may additionally comprise a premixing stepbefore step (1): adding the medicine powder or extract with water,stirring over 10 min at 30˜80° C. to obtain the premixed material,ensuring the homogenization of water. This step may remedy the defectsbrought about by inputted dried powder.

In an embodiment of this invention, said micro drop pills prepared bythe method may be either packaged directly, or prepared into capsuleafter loading into capsule shell. After preparation of capsule, theweighing step for capsule may be additionally employed one by one.High-speed weighing for the loaded capsule one-by-one before packagingis employed so as to eliminate possibly substandard capsules.

In an embodiment of this invention, said method is characterized inthat: it is the first time to creatively combine the techniques ofvibration dropping and air cooling with the fluidization drying coatingmethod to apply to the formulation of drop pill and drop pill capsule.Hence, both producing rate and forming quality of the drop pill areincreased, further simplifying the production process. The advantages ofthe present invention are presented as follows:

1. Using method of vibration dropping and air cooling instead oftraditional drop pill preparation method (gravity/pressure dropping andcoolant cooling)

Utilization of air cooling well met the requirements of high-speeddropping, preparing a micro drop pill (with the particle size of 2.5 mmor smaller) and increasing drug-loading capacity. As a result of this,the drug-loading capacity of drop pill had been increased exponentiallyand the amount and dose of the drop pill matrix reduced dramatically.Moreover, the productivity of the drop pills had been enhanced greatlyfrom traditional rate of 1˜2 pills/s to 1000˜1250 pills/s, and theparticle size ranged from 2 mm˜4 mm to 0.2 mm˜4 mm. It was possible toproduce the micro drop pills that could be loaded into the capsule. Byadjusting the vibration parameters and fluidization coating, thedrug-loading capacity would be increased from about 25% traditionally toabout 50% or more, and therefore the amount of matrix reduced by leapsand bounds.

2. Lowered cost: instead of the traditional coolant of liquid paraffinand silicone oil etc, the low-temperature air, nitrogen or inert gaswere employed to perform cooling, avoiding follow-up steps ofeliminating residual solvent (e.g. step of removing oil). Hence, theoperation process was simplified and totally free of residual organicsolvent. The preparation cost was lowered.

3. The fluidization drying was added, which might not only prevent thedrop pill from adhesion, precipitation of constituents and reducedvolatile oil caused by the storage stage of air cooling method, but alsoreduce drying time (from 4˜24 hours to 2 hours). By using fluidizationcoating, the molten medicine liquid was injected to coat withdrug-loading, further improving the drug-loading capacity. Also, thistechnique of injection was used for coating the drop pills so as torealize the purposes of different techniques (e.g. the sustained releasecoating, film coating and sugar coating etc). Because the fluidizationwas believed to be a mild process, it not only ensured the water toreach a stable value, but also improved the drug-loading capacity andthe uniformity of coating in the drop pills. Unlike the drop pillsprepared by the traditional methods, the fluidization would prevent thedrop pills from being cleft and white-dotted and at same time, the yieldwas increased.

Comparison of the physic-chemical parameters between the micro drop pillof the present invention (CSDP prepared by the method of Example 15) andtraditional drop pill was presented in Table 2.

TABLE 2 Micro drop pill in the present invention Commercially availabledrop pills Weight & Smaller weight, about 4 mg, so as Larger weight, 25mg-27 mg volume to be accurately filled into capsule Drug-loadingDrug-loading 30 wt % (calculated Drug-loading 18-20 wt % capacity basedon dried extract) (calculated based on dried extract) AppearanceReplacing the original cooling Residual cooling liquids on the liquidwith air cooling, ensuring surface of drop pill condensation formingeffect, overcoming the drawbacks of residual cooling liquids EfficiencySuper high-speed vibration and Slower dropping rate than the pressurizeddropping ensuring a vibration dropping, complicated stable delivery ofmaterials, process of eliminating the cooling increasing dropping rate,greatly liquids on the surface, requiring improving the efficiency longtime Release rate Totally mixing the medicine with — the matrix byhomogenizer, dispersing the medicine active ingredients, helping drugabsorption, reducing the pill weight so as to not only be accuratelyfilled into capsule, but also quicken drug release, enhancing clinicalefficacy Roundness & Excellent roundness, the particle Good roundness,particle size of particle size size of 1 mm-2 mm, capable of 3 mm~4 mm,unable to reach preparing drop pills having a 1 mm~2 mm particle size of0.2 mm~4 mm

EXAMPLES

The following examples are offered for purposes of elaboratingexplanation of the present invention only and are not intended to limitthe scope of the invention in any way.

Determination Method of Salvia Miltiorrhiza and Panax NotoginsengExtract

In following Examples, each ingredient of the traditional Chinesemedicine was determined by following method, including the Danshensu,Salvianolic acid T, protocatechuic aldehyde, Salvianolic acid D,rosmarinic acid, Salvianolic acid B, Salvianolic acid A,dihydrotanshinone I, tanshinone I, cryptotanshinone, tanshinone IIA,Panax Notoginseng Saponin R1, Ginsenoside Rg1, Ginsenoside Re,Ginsenoside Rb1 and Ginsenoside Rd.

Determination of Salvianolic Acids and Tanshinones

Preparation of Reference and Tested Solutions

Preparation of reference solution: a certain amount of referencesubstances, including the Danshensu, Salvianolic acid T, protocatechuicaldehyde, Salvianolic acid D, rosmarinic acid, Salvianolic acid B,Salvianolic acid A, dihydrotanshinone I, tanshinone I, cryptotanshinone,tanshinone IIA, were weighed accurately, transferred to 10 ml volumetricflask and diluted with methanol to the scale, which was continued to bediluted as required, shook well and filtered through 0.22 μm membrane togive the reference solution respectively as follows: Danshensu at 0.0315mg/ml, Salvianolic acid T at 0.04596 mg/ml, protocatechuic aldehyde at0.07556 mg/ml, Salvianolic acid D at 0.04385 mg/ml, rosmarinic acid at0.04263 mg/ml, Salvianolic acid B at 0.04248 mg/ml, Salvianolic acid Aat 0.1118 mg/ml, dihydrotanshinone I at 0.02098 mg/ml, tanshinone I at0.02085 mg/ml, cryptotanshinone at 0.02442 mg/ml, tanshinone IIA at0.01992 mg/ml.

Preparation of tested solution: 0.1 g of Salvia Miltiorrhiza and PanaxNotoginseng extract was weighed accurately, transferred to 10 mlvolumetric flask, dissolved with purified water, diluted to scale andfiltered through 0.22 μm membrane to give the tested solution.

Method: 10 μl of reference and tested solutions were respectivelyabsorbed with precision and injected into HPLC to assay.

Chromatographic column: Agilent Zorbax SB C18 (4.6×250 mm, 5 μm);

Flow rate: 0.5 mL/min

Column temperature: 30° C.

Detective wavelength: 281 nm,

The eluting condition was presented in following Table 3.

TABLE 3 A (%) B (%) Time Water (0.02% Acetonitrile (min) formic acid)(0.02% formic acid)  0 90  10 15 80  20 25 75  25 30 74  26 45 54  46 5048  52 62 28  72 70  0 100 76  0 100

Wherein, the retention time of Danshensu, Salvianolic acid T,protocatechuic aldehyde, Salvianolic acid D, rosmarinic acid,Salvianolic acid B, Salvianolic acid A, dihydrotanshinone I, tanshinoneI, cryptotanshinone and tanshinone IIA under wavelength of 281 nm waspresented in FIG. 11 and Table 4.

TABLE 4 Grouping of Retention ingredients time (min) Peak nameSalvianolic acids  9.710 Danshensu 16.908 protocatechuic aldehyde 26.402Salvianolic acid T 28.691 Salvianolic acid D 32.844 rosmarinic acid36.137 Salvianolic acid B 40.047 Salvianolic acid A Tansh nones 66.829dihydrotanshinone I 71.524 tanshinone I 72.021 Cryptotanshinone 75.020tanshinone IIA

Determination of Saponins

Preparation of reference solution: a certain amount of referencesubstances, including the Panax Notoginseng Saponin R1, Ginsenoside Rg1,Ginsenoside Re, Ginsenoside Rb1 and Ginsenoside Rd, were weighedaccurately, into which methanol was added to give the referencesolution, respectively containing 0.5 mg, 2.0 mg, 1.0 mg, 0.5 mg, 0.5mg, 0.5 mg, 1.0 mg per ml.

Preparation of tested solution: 0.1 g of Salvia Miltiorrhiza and PanaxNotoginseng extract was weighed accurately, dissolved with 4% ammoniasolution (10 ml) and passed through D101 macro porous column (innerdiameter: 0.7 cm and height: 5 cm), which was eluted firstly with 30 mlwater, 30 ml methanol (30%) and 10 ml methanol to collect the methanolsolution in 10 volumetric flask, shake well to give the tested solution.

Chromatographic condition and system suitability test: octadecylsilanebonded silica gel was used as bulking agent; acetonitrile was used asmobile phase “A” and water as mobile phase “B”. According to followingTable 5, a gradient elution method was used, and flow rate was at 1.0ml/min, detective wavelength at 203 nm, column temperature at 30° C. andrecording time 75 min.

TABLE 5 mobile phase of gradient elution Time (min) Mobile phase AMobile phase B  0 20 80 25 25 75 60 40 60 70 70 30 75 20 80 80 20 80

Measurement: 10 μl of reference and tested solutions were respectivelyabsorbed with precision and injected into HPLC to assay under aforesaidconditions. The retention time of each ingredient was presented in FIG.12.

Preparation of Traditional Chinese Medicine Composition of the PresentInvention

Example 1

820 g of crude medicine of Salvia Miltiorrhiza was cut into the piecesof 1˜2 cm in length and 160 g of crude medicine of Panax Notoginsengground into particles of 0.18 cm. Sodium bicarbonate accounting for 2.25wt % of total crude medicine was weighed and charged into an extractingtank together with Salvia Miltiorrhiza and Panax Notoginseng and 5 timesof water was added to heat and keep boiling for 2 h and filtered.Resultant residues were extracted for 2^(nd) time by adding with 4 timesof water to heat and keep boiling for 2 h and filtered. The residueswere removed. The extraction solution obtained by two extractions wasconcentrated to a relative density of 1.16-1.20 (80±5° C.) or a relativesugar degree of 48˜52% to give the concentrated liquid. The liquid wasdelivered to the alcohol precipitation tank, into which a proper amountof ethanol was poured to make final ethanol content of 65˜70% andallowed to stand still for 12 hours to precipitate completely. Thesupernatant was separated and the deposit eliminated. The supernatantwas concentrated to give the extract, which was dried to obtain SalviaMiltiorrhiza and Panax Notoginseng extract.

By aforesaid method, the Salvia Miltiorrhiza and Panax Notoginsengextract was determined and the concentration of ingredients waspresented as follows: the Danshensu at 36 mg/g, Salvianolic acid T at 1mg/g, protocatechuic aldehyde at 17 mg/g, Salvianolic acid D at 6 mg/g,rosmarinic acid at 7 mg/g, Salvianolic acid B at 13 mg/g, Salvianolicacid A at 9 mg/g, Panax Notoginseng Saponin R1 at 17 mg/g, GinsenosideRg1 at 24 mg/g, Ginsenoside Re at 3 mg/g, Ginsenoside Rb1 at 18 mg/g andGinsenoside Rd at 4 mg/g, dihydrotanshinone I at 0.3 mg/g, tanshinone I0.7 mg/g, cryptotanshinone at 0.6 mg/g, tanshinone IIA at 2.7 mg/g.

90 g of the Salvia Miltiorrhiza and Panax Notoginseng extract was addedwith 9 g of borneol to give the traditional Chinese medicine.

Example 2

75 g of Salvia Miltiorrhiza and Panax Notoginseng extract obtained fromExample 1 and 25 g of borneol was mixed uniformly to give thetraditional Chinese medicine composition.

Example 3

800.0 g of crude medicine of Salvia Miltiorrhiza and 150.0 g of PanaxNotoginseng were decocted with water under alkaline condition for 3times (pH=9), 1 hour each time and filtered to give filtrate I.Resultant residue was decocted with water for 3 times, 1 hour each timeand filtered to give the filtrate II. Filtrate I and filtrate II werecombined and concentrated. The concentrated liquid was added withethanol to make final ethanol content of 70% and allowed to stand still.The supernatant was filtered to recover the ethanol, which wasconcentrated and dried to obtain Salvia Miltiorrhiza and PanaxNotoginseng extract.

By aforesaid method, the Salvia Miltiorrhiza and Panax Notoginsengextract was determined and the concentration of ingredients waspresented as follows: the Danshensu at 40 mg/g, Salvianolic acid T at 12mg/g, protocatechuic aldehyde at 20 mg/g, Salvianolic acid D at 7 mg/g,rosmarinic acid at 9 mg/g, Salvianolic acid B at 16 mg/g, Salvianolicacid A at 12 mg/g, Panax Notoginseng Saponin R1 at 9 mg/g, GinsenosideRg1 at 28 mg/g, Ginsenoside Re at 4 mg/g, Ginsenoside Rb1 at 22 mg/g andGinsenoside Rd at 6 mg/g, dihydrotanshinone I at 0.4 mg/g, tanshinone I0.8 mg/g, cryptotanshinone at 0.6 mg/g, tanshinone IIA at 2.8 mg/g.

99.9 g of the Salvia Miltiorrhiza and Panax Notoginseng extract wasadded with 0.1 g of borneol to give the traditional Chinese medicine.

Example 4

90 g of Salvia Miltiorrhiza and Panax Notoginseng extract obtained fromExample 3 and 10 g of borneol was mixed uniformly to give thetraditional Chinese medicine composition.

Example 5

750 g of crude medicine of Salvia Miltiorrhiza and 250 g of PanaxNotoginseng were decocted with water under alkaline condition for 2times (pH=7.5), 2 hours each time and filtered to give filtrate I.Resultant residue was decocted with water for 2 times, 2 hours each timeand filtered to give the filtrate II. Filtrate I and filtrate II werecombined and concentrated. The concentrated liquid was added withethanol to make final ethanol content of 70% and allowed to stand still.The supernatant was filtered to recover the ethanol, which wasconcentrated and dried to obtain Salvia Miltiorrhiza and PanaxNotoginseng extract.

By aforesaid method, the Salvia Miltiorrhiza and Panax Notoginsengextract contained the Danshensu, Salvianolic acid T, protocatechuicaldehyde, Salvianolic acid D, rosmarinic acid, Salvianolic acid B,Salvianolic acid A, Panax Notoginseng Saponin R1, Ginsenoside Rg1 ,Ginsenoside Re, Ginsenoside Rb1, Ginsenoside Rd dihydrotanshinone I,tanshinone I, cryptotanshinone and tanshinone IIA respectively at 30mg/g, 9 mg/g, 14 mg/g, 5 mg/g, 5 mg/g, 10 mg/g, 7 mg/g, 5 mg/g, 18 mg/g,2 mg/g, 17 mg/g, 2 mg/g, 0.3 mg/g, 0.7 mg/g, 0.5 mg/g and 2.6 mg/g.

50 g of the Salvia Miltiorrhiza and Panax Notoginseng extract was addedwith 50 g of borneol to give the traditional Chinese medicine.

Example 6

99 g of Salvia Miltiorrhiza and Panax Notoginseng extract obtained fromExample 5 and 1 g of borneol was mixed uniformly to give the traditionalChinese medicine composition.

Example 7

83 weight parts of Salvia Miltiorrhiza and 17 weight parts of PanaxNotoginseng were decocted with water under alkaline condition for 2times (pH=7.5), 2 hours each time and filtered to give filtrate I.Resultant residue was decocted with water for 2 times, 2 hours each timeand filtered to give the filtrate II. Filtrate I and filtrate II werecombined and concentrated. The concentrated liquid was added withethanol to make final ethanol content of 70% and allowed to stand still.The supernatant was filtered to recover the ethanol, which wasconcentrated and dried to obtain Salvia Miltiorrhiza and PanaxNotoginseng extract. 1 weight part of borneol was added to give thetraditional Chinese medicine. Said bomeol was commercially available.

By aforesaid method, the Salvia Miltiorrhiza and Panax Notoginsengextract contained the Danshensu, Salvianolic acid T, protocatechuicaldehyde, Salvianolic acid D, rosmarinic acid, Salvianolic acid B,Salvianolic acid A, Panax Notoginseng Saponin R1, Ginsenoside Rg1 ,Ginsenoside Re, Ginsenoside Rb1, Ginsenoside Rd dihydrotanshinone I,tanshinone I, cryptotanshinone and tanshinone IIA respectively at 40mg/g, 12 mg/g, 20 mg/g, 7 mg/g, 9 mg/g, 16 mg/g, 12 mg/g, 9 mg/g, 28mg/g, 4 mg/g, 22 mg/g, 6 mg/g, 0.4 mg/g, 0.8 mg/g, 0.6 mg/g, 2.8 mg/g.

Example 8

400 g of crude medicine of Salvia Miltiorrhiza was cut into the piecesof 1˜2 cm in length and 80 g of crude medicine of Panax Notoginsengground into particles. Sodium bicarbonate accounting for 3 wt % of totalcrude medicine was weighed and charged into an extracting tank togetherwith Salvia Miltiorrhiza and Panax Notoginseng and 5 times of water wasadded to heat and keep boiling for 2 h±20 min and filtered. Resultantresidues were extracted for 2^(nd) time by adding with 4 times of waterto heat and keep boiling for 1 h±15 min and filtered. The residues wereremoved. The extraction solution obtained by two extractions wasconcentrated to a relative density of 1.16-1.20 (80±5° C.) or a relativesugar degree of 50% to give the concentrated liquid. The liquid wasdelivered to the alcohol precipitation tank, into which a proper amountof ethanol was poured to make final ethanol content of 68% and allowedto stand still for 20 hours to precipitate completely. The supernatantwas separated and the deposit eliminated. The supernatant wasconcentrated to give the extract, which was dried to obtain SalviaMiltiorrhiza and Panax Notoginseng extract.

By aforesaid method, the Salvia Miltiorrhiza and Panax Notoginsengextract contained the Danshensu, Salvianolic acid T, protocatechuicaldehyde, Salvianolic acid D, rosmarinic acid, Salvianolic acid B,Salvianolic acid A, Panax Notoginseng Saponin R1, Ginsenoside Rg1 ,Ginsenoside Re, Ginsenoside Rb1, Ginsenoside Rd dihydrotanshinone I,tanshinone I, cryptotanshinone and tanshinone IIA respectively at 20mg/g, 5 mg/g, 10 mg/g, 2 mg/g, 0.2 mg/g, 5 mg/g, 5 mg/g, 2 mg/g, 1 mg/g,1 mg/g, 10 mg/g, 1 mg/g, 0.1 mg/g, 0.5 mg/g, 0.2 mg/g, 1 mg/g.

90 g of the Salvia Miltiorrhiza and Panax Notoginseng extract was addedwith 9 g of borneol to give the traditional Chinese medicine.

Example 9

500 g of crude medicine of Salvia Miltiorrhiza was cut into the piecesof 1˜2 cm in length and 102 g of crude medicine of Panax Notoginsengground into particles. Sodium bicarbonate accounting for 2.5 wt % oftotal crude medicine was weighed and charged into an extracting tanktogether with Salvia Miltiorrhiza and Panax Notoginseng and 6 times ofwater was added to heat and keep boiling for 2 h and filtered. Resultantresidues were extracted for 2^(nd) time by adding with 6 times of waterto heat and keep boiling for 1 h and filtered. The residues wereremoved. The extraction solution obtained by two extractions wasconcentrated to a relative density of 1.16-1.20 (80±5° C.) or a relativesugar degree of 48% to give the concentrated liquid. The liquid wasdelivered to the alcohol precipitation tank, into which a proper amountof ethanol was poured to make final ethanol content of 65% and allowedto stand still for 24 hours to precipitate completely. The supernatantwas separated and the deposit eliminated. The supernatant wasconcentrated to give the extract, which was dried to obtain SalviaMiltiorrhiza and Panax Notoginseng extract.

By aforesaid method, the Salvia Miltiorrhiza and Panax Notoginsengextract contained the Danshensu, Salvianolic acid T, protocatechuicaldehyde, Salvianolic acid D, rosmarinic acid, Salvianolic acid B,Salvianolic acid A, Panax Notoginseng Saponin R1, Ginsenoside Rg1,Ginsenoside Re, Ginsenoside Rb1, Ginsenoside Rd dihydrotanshinone I,tanshinone I, cryptotanshinone and tanshinone IIA respectively at 60mg/g, 20 mg/g, 30 mg/g, 10 mg/g, 10 mg/g, 20 mg/g, 20 mg/g, 10 mg/g, 40mg/g, 5 mg/g, 40 mg/g, 10 mg/g, 0.5 mg/g, 1 mg/g, 1 mg/g, 5 mg/g.

99.9 g of the Salvia Miltiorrhiza and Panax Notoginseng extract wasmixed uniformly with 0.1 g of bomeol to give the traditional Chinesemedicine.

Preparation of Traditional Chinese Medicine Preparation

Example 10

0.5 g of traditional Chinese medicine composition prepared by any onemethod of Examples 1˜9 was mixed uniformly with 10.5 g of PEG-6000,molten by heating and delivered to the dropping machine to acquiremedicine drops by means of dropping the medicine solution into liquidparaffin at 6˜8° C. Residual liquid paraffin was removed to give 400micro drop pills.

Example 11

0.5 g of traditional Chinese medicine composition prepared by any onemethod of Examples 1˜9, 4.5 g of glucose, 0.9 g of sodium thiosulphateand 1 ml of distilled water were mixed uniformly to give 500 injectablelyophilized powders by lyophilizing.

Example 12

0.5 g of traditional Chinese medicine composition prepared by any onemethod of Examples 1˜9, 5.5 g of mannitol, 0.9 g of EDTA calciumdisodium and 2 ml of distilled water were mixed uniformly to give 300injectable lyophilized powders by lyophilizing.

Example 13

0.5 g of traditional Chinese medicine composition prepared by any onemethod of Examples 1˜9, 50 g of starch and 50 g of sucrose were mixeduniformly to give the tablets by compression after granulating.

Example 14

0.5 g of traditional Chinese medicine composition prepared by any onemethod of Examples 1˜9, 50 g of starch and 50 g of sucrose were mixeduniformly to give the capsules by filling into capsules.

Preparation of the Micro Drop Pill

Example 15

82.5 g of traditional Chinese medicine composition prepared by themethod of Example 1 and 165 g of PEG-6000 were prepared.

(1) Pre-mixing step: the traditional Chinese medicine composition wasadded with water to pre-mix, stirred in the soaking tank at 40±10° C.over 60 min to make the water content of the composition at 13.0 wt % togive the premixed material for later use;

(2) Melting step: PEG-6000 was firstly input into the melting tank,pre-molten by heating to 90° C., into which the pre-mixed material wasadded and the resultant liquid was mixed by low-speed homogenization(3200 rpm); after mixing, the homogenization rate was increased to 5000rpm to melt for 6 min; during the melting process, temperature of theliquid was kept at 80±5° C. to give the molten medicine liquid;

(3) Dropping step: aforesaid molten medicine liquid was delivered to thedripper, the vibration frequency of dripper adjusted to 137 Hz andtemperature of dripper adjusted to 80° C.; the liquid was delivered tothe dripper under pressure (1.8 Bar), from which the liquid was droppeddown by means of vibration; said dropping rate was matched with themelting rate in step (1); and

(4) Condensation step: the drops were cooled in cooling duct with thelow-temperature inert gas at −115±5° C. to cool the liquid to form thesolid drop pill;

(5) Drying step: resultant drop pill was fluidization dried; until thedrop pill reached better fluidization state, the temperature wasincreased to 25° C. to dry for 60 min, continuously increased to 55° C.to dry for 30 min, and deceased to 30° C. or lower to discharge to givethe intermediate blank drop pill with the water content controlled inthe range of 3.0˜7.0 wt %;

(6) Coating step: the amount of coating powder was calculated based oncoating feed capacity and formula; Opadry accounting for 4 wt % of theblank drop pill was used to prepare the 18 wt % coating solution andstirred for 45 min; inlet air temperature was initially set to 25° C.;after the standard blank drop pills were loaded into the fluidized bed,the inlet air temperature was increased to 48° C.; until the temperatureof the drop pill grew to 38° C., the coating was started; thetemperature was kept in the range of 35˜45° C. during the coating anddecreased to 30° C. or lower after coating; the pills were discharged,screened to get the intermediate coating the drop pills with the coatingweight of 3.3±0.7% and the water content in the range of 3.0˜7.0 wt %.

(7) Loading into capsule and packaging step: the resultant micro droppills with the particle size of 1.0 mm˜2.0 mm were loaded into thecapsules; 100% of capsules were on-line checkweighed with a capsulecheckweigher, packaged to give the final product.

Wherein, during the process of dropping, formation of drop pill wasmeasured visually by using stroboscopic illumination to performreal-time monitoring and adjustment. In order to improve the uniformityand roundness of the drop pills, the step of screening and regulatingmight be added.

Example 16

Except that the ratio of traditional Chinese medicine composition toPEG-6000 was 1:5, the CSMDP was prepared by the method of Example 15.

Example 17

Except that the ratio of traditional Chinese medicine composition toPEG-6000 was 5:1, the CSMDP was prepared by the method of Example 15.

Example 18

Following materials were taken: 82.5 g of traditional Chinese medicinecomposition prepared by Example 1 and 165 g of a mixture of cyclodextrinand agar (1:1). CSMDP was prepared according to the following method:

(1) Melting step: the mixture of cyclodextrin and agar (1:1) was used asa matrix, charged into the homogenizer with the traditional Chinesemedicine composition to homogenize at 1000 rpm for 1 min to give thematerial; the material was molten at 3000 rpm for 1 min; during themelting process, the temperature was kept at 60° C. to obtain the moltenmedicine liquid;

(2) Dropping step: the molten medicine liquid was delivered to a dripperand dropped by means of vibration dropping at dripper temperature of 70°C. at a vibration frequency of 50 Hz under a dropping pressure of 0.5Bar; said dropping rate was matched with the melting rate in step (1);and

(3) Condensation step: the medicine drops were cooled with cooling gasrapidly to solidify to obtain the blank drop pill having a particle sizeof 0.2 mm; said temperature of cooling gas was 0° C.

Example 19

Following materials were taken: 82.5 g of traditional Chinese medicinecomposition prepared by Example 1 and 165 g of a mixture of Arabic gumand lactose (1:1). CSMDP was prepared according to the following method:

(1) Melting step: the mixture of Arabic gum and lactose (1:1) was usedas a matrix, charged into the homogenizer with the traditional Chinesemedicine composition to homogenize at 5000 rpm for 200 min to give thematerial; the material was molten at 10000 rpm for 100 min; during themelting process, the temperature was kept at 100° C. to obtain themolten medicine liquid;

(2) Dropping step: the molten medicine liquid was delivered to a dripperand dropped by means of vibration dropping at dripper temperature of300° C. at a vibration frequency of 300 Hz under a dropping pressure of4.0 Bar; said dropping rate was matched with the melting rate in step(1); and

(3) Condensation step: the medicine drops were cooled with cooling gasrapidly to solidify to obtain the blank drop pill having a particle sizeof 4.0 mm; said temperature of cooling gas was −150° C.

Example 20

Following materials were taken: 82.5 g of traditional Chinese medicinecomposition prepared by Example 1 and 165 g of lactitol. CSMDP wasprepared according to the following method:

(1) Melting step: the lactitol was used as a matrix, charged into thehomogenizer with the traditional Chinese medicine composition tohomogenize at 2500 rpm for 100 min to give the material; the materialwas molten at 6000 rpm for 50 min; during the melting process, thetemperature was kept at 80° C. to obtain the molten medicine liquid;

(2) Dropping step: the molten medicine liquid was delivered to a dripperand dropped by means of vibration dropping at dripper temperature of150° C. at a vibration frequency of 150 Hz under a dropping pressure of2 Bar; said dropping rate was matched with the melting rate in step (1);and

(3) Condensation step: the medicine drops were cooled with cooling gasrapidly to solidify to obtain the blank drop pill having a particle sizeof 2 mm; said temperature of cooling gas was −100° C.;

(4) Drying step: resultant drop pill was fluidization dried at 50° C.for 2 hours to give the dried blank drop pill;

(5) Coating step: resultant dried blank drop pills were coated at 40° C.in fluidized bed to obtain coated drop pill; said ratio of coatingmaterial to the dried blank pills was 1:25; the concentration of saidcoating solution was 10 wt % and said coating material was Opadry.

Example 21

Following materials were taken: 82.5 g of traditional Chinese medicinecomposition and 165 g of PEG-8000. CSMDP was prepared according to thefollowing method:

Said traditional Chinese medicine composition powder was added withwater and stirred at 60° C. for 10 min or more to obtain the pre-mixedtraditional Chinese medicine composition.

(1) Melting step: the PEG-8000 and said pre-mixed traditional Chinesemedicine composition were charged into the homogenizer to mix at 2500rpm for 100 min to give the material; the material was moltenhomogenizedly at 6000 rpm for 50 min; during the melting process, thetemperature was kept at 80° C. to obtain the molten medicine liquid;

(2) Dropping step: the molten medicine liquid was delivered to a dripperand dropped by means of vibration dropping at dripper temperature of150° C. at a vibration frequency of 150 Hz under a dropping pressure of2 Bar; said dropping rate was matched with the melting rate in step (1);and

(3) Condensation step: the medicine drops were cooled with cooling gasrapidly to solidify to obtain the blank drop pill having a particle sizeof 2 mm; said temperature of cooling gas was −100° C.;

(4) Drying step: resultant drop pill was fluidization dried at 50° C.for 2 hours to give the dried blank drop pill;

(5) Coating step: resultant dried blank drop pills were coated at 40° C.in fluidized bed to obtain coated drop pill; said ratio of coatingmaterial to the dried blank pills was 1:25; the concentration of saidcoating solution was 10 wt % and said coating material was shellac.

Example 22

Following materials were taken: 92 g of traditional Chinese medicinecomposition and 270 g of PEG-1000. CSMDP was prepared according to thefollowing method:

Said traditional Chinese medicine composition powder was added withwater and stirred at 30° C. for 10 min or more to obtain the pre-mixedtraditional Chinese medicine composition.

(1) Melting step: the PEG-1000 and said pre-mixed traditional Chinesemedicine composition were charged into the homogenizer to mix at 2500rpm for 100 min to give the material; the material was moltenhomogenizedly at 6000 rpm for 20 min; during the melting process, thetemperature was kept at 100° C. to obtain the molten medicine liquid;

(2) Dropping step: the molten medicine liquid was delivered to a dripperand dropped by means of vibration dropping at dripper temperature of 70°C. at a vibration frequency of 100 Hz under a dropping pressure of 1.0Bar; acceleration at 1 G and dropping rate at 10 Kg/h; said droppingrate was matched with the melting rate in step (1); and

(3) Condensation step: the medicine drops were cooled with cooling gasrapidly to solidify to obtain the blank drop pill having a particle sizeof 2 mm; said temperature of cooling gas was −80° C.;

(4) Drying step: resultant drop pill was dried by gradient-risingtemperature drying method, fluidized at −20° C., dried at 15° C. for 10min, 35° C. for 10 min and at 55° C. for 30 min to give the dried blankdrop pill;

(5) Coating step: resultant dried blank pills were coated at 40° C. influidized bed to obtain coated drop pill; said ratio of coating materialto the dried blank pills was 1:25; the concentration of said coatingsolution was 10 wt % and said coating material was CAP.

Example 23

Following materials were taken: 105 g of traditional Chinese medicinecomposition and 35 g of a mixture of PEG-4000:PEG-6000 (1:1). CSMDP wasprepared according to the following method:

Said traditional Chinese medicine composition powder was added withwater and stirred at 80° C. for 10 min or more to obtain the pre-mixedtraditional Chinese medicine composition.

(1) Melting step: the mixture of PEG-4000:PEG-6000 (1:1) and saidpre-mixed traditional Chinese medicine composition were charged into thehomogenizer to mix at 2500 rpm for 100 min to give the material; thematerial was molten homogenizedly at 6000 rpm for 80 min; during themelting process, the temperature was kept at 80° C. to obtain the moltenmedicine liquid;

(2) Dropping step: the molten medicine liquid was delivered to a dripperand dropped by means of vibration dropping at dripper temperature of100° C. at a vibration frequency of 200 Hz under a dropping pressure of3.0 Bar; acceleration at 20 G and dropping rate at 40 Kg/h; saiddropping rate was matched with the melting rate in step (1); and

(3) Condensation step: the medicine drops were cooled with cooling gasrapidly to solidify to obtain the blank drop pill having a particle sizeof 2 mm; said temperature of cooling gas was −120° C.;

(4) Drying step: resultant drop pill was dried by gradient-risingtemperature drying method, fluidized at 30° C., dried at 35° C. for 120min, at 55° C. for 60 min and at 100° C. for 60 min to give the driedblank drop pill;

(5) Coating step: resultant dried blank pills were coated at 35° C. influidized bed to obtain coated drop pill; said ratio of coating materialto the dried blank pills was 1:25; the concentration of said coatingsolution was 10 wt % and said coating material was methyl acrylate.

Example 24

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 600 g of xylitolas drop pill matrix.

(1) Melting step: the xylitol was firstly charged into the melting tankand heated to 90° C. to pre-melt, into which said pre-mixed traditionalChinese medicine composition was charged to mix to give the moltenmedicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 40° C. and a vibration frequency of 50 Hz, saidmolten medicine liquid flowed into the dripper and dropped from thebottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −20° C.;

(4) Drying & coating step: resultant solid drop pill was fluidizationdried and drug-loading coated to give the coated micro drop pill withthe particle size of 0.2 mm˜1.0 mm; said drying temperature was 75° C.;and

(5) Packaging step: said micro drop pills with the particle size of 0.2mm˜1.0 mm were loaded into the capsules; 100% of capsules were on-linecheckweighed with a capsule checkweigher and packaged to give the finalproduct.

Wherein, during the process of dropping, formation of drop pill wasmeasured visually by using stroboscopic illumination to performreal-time monitoring and adjustment. In order to improve the uniformityand roundness of the drop pills, the step of screening and regulatingmight be added.

Example 25

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 3000 g of amixture of PEG-6000 and PEG-4000 as drop pill matrix.

(1) Melting step: the mixture of PEG-6000 and PEG-4000 was firstlycharged into the melting tank and pre-molten by heating to 120° C., intowhich said pre-mixed traditional Chinese medicine composition wascharged to well mix to give the molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 80° C. and a vibration frequency of 20 Hz, saidmolten medicine liquid flowed into the dripper and dropped from thebottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −80° C.;

(4) Drying & coating step: resultant solid drop pill was fluidizationdried and drug-loading coated to give the coated micro drop pill withthe particle size of 0.5 mm˜1.0 mm; said drying temperature was 150° C.;and

(5) Packaging step: said micro drop pills were loaded into the capsules;100% of capsules were on-line checkweighed with a capsule checkweigherand packaged to give the final product.

Wherein, during the process of dropping, formation of drop pill wasmeasured visually by using stroboscopic illumination to performreal-time monitoring and adjustment. In order to improve the uniformityand roundness of the drop pills, the step of screening and regulatingmight be added.

Example 26

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of bomeol and 120 g of PEG-1000as drop pill matrix.

(1) Melting step: the PEG-1000 was firstly charged into the melting tankand pre-molten by heating to 40° C., into which said pre-mixedtraditional Chinese medicine composition was charged to well mix to givethe molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 40˜60° C. and a vibration frequency of 200 Hz,said molten medicine liquid flowed into the dripper and dropped from thebottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −100° C.;

(4) Drying & coating step: resultant solid drop pill was fluidizationdried and drug-loading coated, fluidized at 20° C., dried at 25° C. for60 min, at 45° C. for 30 min and at 55° C. for 30 min to give the coatedmicro drop pill with the particle size of 3.0 mm˜4.0 mm; and

(5) Packaging step: said micro drop pills were loaded into the capsules;100% of capsules were on-line checkweighed with a capsule checkweigherand packaged to give the final product.

Wherein, during the process of dropping, formation of drop pill wasmeasured visually by using stroboscopic illumination to performreal-time monitoring and adjustment. In order to improve the uniformityand roundness of the drop pills, the step of screening and regulatingmight be added.

Example 27

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 3000 g of amixture of PEG-6000 and PEG-4000 as drop pill matrix.

(1) Melting step: the mixture of PEG-6000 and PEG-4000 was firstlycharged into the melting tank and pre-molten by heating to 120° C., intowhich said pre-mixed traditional Chinese medicine composition wascharged and poured into the homogenizer to mix at 1000 rpm for 1 min andmelt at 3000 rpm for 1 min, during the melting process, the temperaturewas kept at 60° C. to obtain the molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 70° C., a vibration frequency of 50 Hz anddropping pressure of 0.5 Bar, said molten medicine liquid flowed intothe dripper and dropped from the bottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was 0° C.;

(4) Drying & coating step: resultant solid drop pill was fluidizationdried and drug-loading coated to give the coated micro drop pill withthe particle size of 0.2 mm; said drying temperature was 150° C.; and

(5) Packaging step: said micro drop pills were loaded into the capsules;100% of capsules were on-line checkweighed with a capsule checkweigherand packaged to give the final product.

Example 28

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 1800 g of PEG-6000as drop pill matrix.

(1) Melting step: the PEG-6000 was firstly charged into the melting tankand pre-molten by heating to 120° C., into which said pre-mixedtraditional Chinese medicine composition was charged and poured into thehomogenizer to mix at 5000 rpm for 200 min and melt at 10000 rpm for 1min, during the melting process, the temperature was kept at 100° C. toobtain the molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 300° C., a vibration frequency of 300 Hz anddropping pressure of 4.0 Bar, said molten medicine liquid flowed intothe dripper and dropped from the bottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −150° C.;

(4) Drying & coating step: resultant solid drop pill was fluidizationdried and drug-loading coated to give the coated micro drop pill withthe particle size of 4.0 mm; said drying temperature was 150° C.; and

(5) Packaging step: said micro drop pills were loaded into the capsules;100% of capsules were on-line checkweighed with a capsule checkweigherand packaged to give the final product.

Example 29

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 2400 g of PEG-4000as drop pill matrix.

(1) Melting step: the PEG-4000 was firstly charged into the melting tankand pre-molten by heating to 120° C., into which said pre-mixedtraditional Chinese medicine composition was charged, homogenized at3000 rpm for 10 min and molten homogenizedly at 4000 rpm for 5 min,during the melting process, the temperature was kept at 70˜90° C. toobtain the molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 70° C., a vibration frequency of 90 Hz anddropping pressure of 1.0 Bar, said molten medicine liquid flowed intothe dripper and dropped from the bottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −140° C.; and

(4) Drying step: resultant solid drop pill was fluidization dried togive the micro drop pill with the particle size of 1.0 mm; said dryingtemperature was 150° C.

Example 30

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 2400 g of PEG-4000as drop pill matrix.

(1) Melting step: the PEG-4000 was firstly charged into the melting tankand pre-molten by heating to 120° C., into which said pre-mixedtraditional Chinese medicine composition was charged, homogenized at4000 rpm for 60 min and molten homogenizedly at 9000 rpm for 30 min,during the melting process, the temperature was kept at 90° C. to obtainthe molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 100° C., a vibration frequency of 200 Hz anddropping pressure of 3.0 Bar, said molten medicine liquid flowed intothe dripper and dropped from the bottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −140° C.; and

(4) Drying step: resultant solid drop pill was fluidization dried togive the micro drop pill with the particle size of 2.0 mm; said dryingtemperature was 150° C.

Example 31

Following materials were taken: 600 g of traditional Chinese medicinecomposition prepared by Example 1, 5 g of borneol and 2000 g of PEG-6000as drop pill matrix.

(1) Melting step: the PEG-6000 was firstly charged into the melting tankand pre-molten by heating to 90° C., into which said pre-mixedtraditional Chinese medicine composition was charged to well mix to givethe molten medicine liquid;

(2) Dropping step: under pressure the molten medicine liquid wasdelivered to a dripper that was heated and preserved by steam jacket; atdripper temperature of 80° C. and a vibration frequency of 50 Hz, saidmolten medicine liquid flowed into the dripper and dropped from thebottom;

(3) Condensation step: the medicine drops were cooled in a cooling ductwith low-temperature inert gas to solidify to obtain the solid droppill; said cooling temperature was −20° C.;

(4) Drying & coating step: resultant solid drop pill was fluidizationdried and drug-loading coated give the coated micro drop pill with theparticle size of 1.0 mm˜2.0 mm; said drying temperature was 75° C.; and

(5) Packaging step: said micro drop pills were loaded into the capsules;100% of capsules were on-line checkweighed with a capsule checkweigherand packaged to give the final product.

Wherein, during the process of dropping, formation of drop pill wasmeasured visually by using stroboscopic illumination to performreal-time monitoring and adjustment. In order to improve the uniformityand roundness of the drop pills, the step of screening and regulatingmight be added.

As found in the study by the inventors, compared with existing CSDP, theCSMDP prepared by the methods disclosed in the EXAMPLES 15˜31 had themerits of good efficacy, high bioavailability, reduced administrationdose and good compliance to the patients.

Preparation of Salvianolic Acid T

Example 32

Salvia Miltiorrhiza was transferred to an herbal decocting pot, intowhich 6 times of 0.3% (w/v) sodium bicarbonate aqueous solution based onthe amount of Salvia Miltiorrhiza was added, decocted for 2.5 h andfiltered to give the filtrate. The filtrate was concentrated to obtainthe aqueous extract with relative density of 1.22 (80° C.).

The aqueous extract was added with 95% (v/v) ethanol to make the finalethanol content as 60% (v/v) (25° C.) and allowed to stand still for 24h to give the supernatant. The supernatant was concentrated underreduced pressure to obtain the ethanol-precipitated extract with arelative density of 1.32 (60° C.).

The ethanol-precipitated extract was dissolved with water, passedthrough AB-8 macroporous resin column and eluted with aqueoushydrochloric acid solution (pH=3.0) until the eluent was nearlycolorless. Later, 5 times of 95% (v/v) ethanol based on the columnvolume was used to elute the column and the eluent was concentrated togive the extract with no smell of alcohol.

The extract obtained from previous step was dissolved with mobile phase(acetonitrile:water:formic acid=15:85:1 by volume) and purified withNOVASEP LC80˜600 dynamic axial high-pressure preparative LC. C18reverse-phase chromatographic column (10 μm, YMC Inc.) was used asstationary phase to carry out the isocratic elution with the mobilephase of acetonitrile:water:formic acid=15:85:1 by volume. The flow ratewas at 300 mL/min and detective wavelength at 280 nm. The process ofelution was monitored by using HPLC to collect the fraction between21.2˜24.0 min and concentrate to dry with the rotary evaporator toobtain salvianolic acid T.

Afore-obtained salvianolic acid T was dissolved with mobile phase(acetonitrile:water:formic acid=17:83:1 by volume) and Waters Prep 400preparative LC was used to carry out chiral isomer separation. Thechromatographic column was CHIRALCEL® OD-RH reverse-phase chiral column(250×20 mm, 5 am) and the mobile phase of acetonitrile:water:formicacid=17:83:1 by volume was used to perform isocratic elution. The flowrate was at 25 mL/min and detective wavelength at 280 nm. The process ofelution was monitored by using HPLC to collect the fraction of(S)-salvianolic acid T between retention time of 19.5˜21.1 min and(R)-salvianolic acid T between retention time of 23.9˜25.3 min. Theeluent was concentrated with rotary evaporator at 30° C. and lyophilizedto obtain the pure product of (S)- and (R)-salvianolic acid T.

By using a high-resolution mass spectrometry, a quasi-molecular ion peakof (S)-salvianolic acid T was at m/z 537.1033 and (R)-salvianolic acid Tat m/z 537.1032.

NMR data assignments for (S)-salvianolic acid T and (R)-salvianolic acidT were seen in the following tables.

TABLE 6 ¹H (DMSO, J Hz) data assignment for the (R)-salv anolic acid T¹H-¹H No. δ_(H) Δc COSY HMBC 1 — 123.7 H-5, H-8 2 — 126.4 H-6, H-7, H-7″3 — 142.9 H-5 4 — 147.7 H-5, H-6 5 6.85 (1H, d, 8.5 Hz) 115.0 H-6 6 7.31(1H, d, 8.5 Hz) 118.4 H-5 H-7 7 7.41 (1H, d, 15.5 Hz) 143.7 H-8 H-6 86.27 (1H, d, 15.5 Hz) 113.9 H-7 H-7 9 — 166.0 H-7, H-8, H-8′ 1' — 127.1H-2′, H-5′, H- 8′, H-7′ 2′ 6.62 (1H, s) 116.5 H-6′ H-6′ 3′ — 143.9 H-2′,H-5′ 4′ — 144.8 H-2′, H-5′, H-6′ 5′ 6.63 (1H, d, 8.0 Hz) 115.5 H-6′ H-6′6′ 6.47 (1H, d, 8.0 Hz) 120.0 H-2′, 5′ H-2′, H-5′ 7′ 2.89 (2H, ddd,14.0,  36.0 H-8′ H-2′, H-5′, 8.0, 4.5 Hz) H-6′, H-8′ 8′ 4.93 (1H, dd,8.0, 4.5 72.8 H-7′ H-7′ Hz) 9′ — 170.6 H-7′, H-8′ 1″ — 126.0 H-2″ 2″6.44 (1H, d, 2.0 Hz) 117.3 H-6″ H-6″, H-7″ 3″ — 144.8 H-2″, H-5″ 4″ —147.2 H-2″, H-5″, H-6″ 5″ 6.55 (1H, d, 8.5 Hz) 115.3 H-6″ 6″ 6.43 (1H,dd, 8.5, 2.0 122.9 H-2″, 5″ H-2″, H-7″ Hz) 7″ 7.69 (1H, s) 141.1 H-6″ 8″— 123.4 H-7″ 9″ — 168.4 H-7″

TABLE 7 ¹H (DMSO, J Hz) data assignment for the (S)-salvianolic acid T¹H-¹H No. δ_(H) δc COSY HMBC 1 — 123.8 H-5, H-8 2 — 126.3 H-6, H-7, H-7″3 — 142.9 H-5 4 — 147.7 H-5, H-6 5 6.85 (1H, d, 8.5 Hz) 115.0 H-6 6 7.29(1H, d, 8.5 Hz) 118.4 H-5 H-7 7 7.41 (1H, d, 15.5 Hz) 143.7 H-8 H-6 86.27 (1H, d, 15.5 Hz) 114.0 H-7 H-7 9 — 165.9 H-7, H-8, H-8' 1′ — 127.2H-2′, H-5′, H- 8′, H-7′ 2′ 6.62 (1H, s) 116.5 H-6′ H-6′, H-7′ 3′ — 143.9H-2′, H-5′, H-6′ 4′ — 144.9 H-2′, H-5′ 5′ 6.63 (1H, d, 8.0 Hz) 115.5H-6′ 6′ 6.45 (1H, d, 8.0 Hz) 120.1 H-2′, 5′ H-2′, H-5′, H-7′ 7′ 2.87(2H, ddd, 14.0,  36.1 H-8′ H-2′, H-5′, H- 8.0, 4.0 Hz) 6′, H-8′ 8′ 4.92(1H, dd, 8.0, 4.0  72.9 H-7′ H-7′ Hz) 9′ — 170.6 H-7′, H-8′ 1″ — 126.0H-5″ 2″ 6.43 (1H, d, 2.0 Hz) 117.3 H-6″ H-6″, H-7″ 3″ — 144.8 H-2″, H-5″4″ — 147.2 H-2″, H-5″, H-6″ 5″ 6.55 (1H, d, 9.0 Hz) 115.3 H-6″ 6″ 6.43(1H, dd, 8.5, 2.0 122.9 H-2″, 5″ H-2″, H-7″ Hz) 7″ 7.69 (1H, s) 141.1H-2″, H-6″ 8″ — 123.3 9″ — 168.4 H-7″

In order to better prove the merits of the present invention, the trialwas presented as follows:

Trial Example 1

1. Materials

1.1 Animals:

SD male rats, weighing 200 g, were purchased from Beijing WeitonglihuaExperimental Animal Co., Ltd, with certification No.: SCXK (JING)2007˜0001.

Rabbits, male, weighing 1.7˜2.0 kg, were purchased from QinglongshanAnimal Reproduction Plant, Jiangning Country, Nanjing with certificationNo.: SCXK (SU) 2007-2008.

1.2 Drugs and Reagents

The Salvia Miltiorrhiza and Panax Notoginseng extracts were divided intotwo types, which were prepared by the method of Example 1, Extract A(with bomeol) and Extract B (without bomeol). Chloral hydrate andtriphenyl tetrazolium chloride (TTC) were used.

Aspirin enteric-coated tablet was purchased from BaijingyuPharmaceutical Inc, Nangjing. Batch number was 111001.

Arachidonic acid (AA) was provided by Sigma Inc in specification of 10mg/bottle, and batch number was 1001126252.

Monosodium adenosine diphosphate (ADP) was provided by Shanghai BoaoBio-tech Inc (Imported). Batch number was 990527.

Collagen was provided by Sigma Inc in specification of 10 mg/bottle, andbatch number was 1001162038.

2. Protocol

2.1 Acute Myocardial Infarction Experiment in Rats

32 rats were randomly divided into groups according to the body weight:the blank group, model group, group A (with bomeol) and group B (withoutbomeol); 8 rats in each group.

After grouping, all animals were administrated intragastrically for 1week, which was seen in Table 8. On 8^(th) day, the animals wereanesthetized by intraperitoneal injection of 10% chloral hydrate (3ml/kg) and fixed on a small plate in a supine position. Conductors wereinserted under the skin of right forelimb and both hind limbs, which wasconnected with the MedLab-U/8c bio-signal collecting-processing systemto record the ECG of rats. Hair on front wall of left chest was clipped.Oral tracheal cannula was performed and the animal respirator wasconnected at respiratory frequency of 80 breaths/min, tidal volume 3ml/100 g and I:E=1:2. Chest on left front chest lateral side was incisedto cut 3^(rd) rib and the pericardium carefully lifted with forceps totear apart. Left coronary vein trunk pass between the lower edge of leftatrial appendage and pulmonary artery cone was observed in most ofanimals, accompanied with LAD. Medical suture (4-0) was used to ligateLAD and a small amount of myocardial tissue 1˜2 mm from the low edge ofleft atrial appendage inside the interventricular sulcus in the vicinityof left coronary vein trunk. Chest was closed layer by layer. Thetracheal tube was detubated until the respiration was recovered in rats.

Testing index: after 4 h ligation, the animals were euthanized. Thehearts were taken out and washed with 0.9% sodium chloride injection toabsorb the water. Along the coronary sulcus, the atrium was cut to weighwet ventricular mass. The heart was sliced into 1 mm thickness ofmyocardial sections in parallel from the apex to the base portion alongventricular ditch. Obtained myocardium was placed in TTC colorant to dyefor 15 min on 37° C. thermal water bath. Normal myocardium was dyed redand infarcted area white. Wet mass in each section of infarcted area wasweighed to calculate the myocardial infarction rate (MIR).

TABLE 8 grouping and administrating Admin- istration Groups dosage Dosetime Sham operation 1 ml/100 g 7 d Model group 1 ml/100 g 7 d Group A83.7 mg/kg 1 ml/100 g 7 d Group B 83.7 mg/kg 1 ml/100 g 7 d

2.2 Platelet Aggregation Rate Trial in Rabbits

The rabbits were randomly grouped into 4 groups: the model group wasgiven with distilled water, the aspirin group (60 mg/ml), Extract Agroups of low dose and high dose at 42 and 84 mg/kg (respectively 1˜2times of clinic equivalent dosage), intragastrically administrated, oncea day for 7 consecutive days. The volume of medicine administrated was 1ml/kg body weight. 60 min after intragastric administration on 7^(th)day, the animals were anesthetized locally, blooded through carotidartery, anticoagulated with sodium citrate (3.8%) 1:9 and centrifugatedat 1000 r/min for 10 min. Platelet-rich plasma (PRP) was taken and theremain centrifugated at 3000 r/min to take platelet-poor plasma (PPP.Aggregation was induced by ADP (final concentration 3 μg/ml), AA (finalconcentration 80 μg/ml) and collagen (5 μg/ml). STEELIEX plateletaggregation & coagulation factor analyzer was used to measure themaximum platelet aggregation rate and to calculate inhibition rateaccording to following formula.

$\begin{matrix}\text{Platelet~~aggregation} \\\text{inhibiting~~rate~~(\%)}\end{matrix} = {\frac{\begin{matrix}{\text{Platelet~~aggregation~~rate~~in~~model~~group}{\; -}\text{~~Platelet}} \\\text{aggregation~~rate~~in~~treatment~~group}\end{matrix}}{\text{Platelet~~aggregation~~rate~~in~~model~~group}} \times 100}$

3. Results

3.1 Experimental Results of Myocardial Infarction in Rats

The results were in Table 9. 7 days after pre-administration, comparedwith the model group (0.1209±0.0199 g), the weights of myocardialinfarction in group A and group B (0.0685±0.0182 g, 0.0923±0.0191 g)were decreased obviously, having statistical significance. According tothe results of inter-group comparison, the ratio of myocardialinfarction in group A was much less than that in group B, havingsignificant difference between two groups (p<0.05).

TABLE 9 effect of Salvia Militiorrhiza and Panax Notoginseng extract onweight of myocardial infarction in rabbits (n = 6) Wet weight Averagewet Average wet of infarction/ weight of weight of wet weight of Dosewhole heart myocardial whole heart × Group (mg/kg) (g) infarction (g)100% (%) Blank 0.887 ± 0.044 0 0.00 ± 0.00  group Model 0.926 ± 0.0940.121 ± 0.020   13.03 ± 1.61   group Group A 83.7 0.872 ± 0.046 0.069 ±0.018*  7.91 ± 2.21* Group B 83.7 0.925 ± 0.127 0.092 ± 0.019*# 10.04 ±1.87*# Note: compared with the model group, *p < 0.05; compared withGroup A, #p < 0.05

3.2 Effect on Platelet Aggregation Rate in Rabbits

As shown in Table 10, Extract A was proven to have inhibitory effect onADP-induced platelet aggregation in rabbits, which, compared with theblank group, had a significant difference. Compared with the aspiringroup, no significant difference was found in the group A in inhibitingADP-induced platelet aggregation.

TABLE 10 effect of Extract A on ADP-induced platelet aggregation inrabbits (x ± s, n = 8) Platelet aggregation Group Dose (mg/kg) rate (%)Blank group  0 30.58 ± 5.35 Aspirin group 60 19.15 ± 4.08** Group A-lowdose 42 24.33 ± 5.21* Group A-high dose 84 20.69 ± 3.47** *P < 0.05, **P< 0.01, compared with the blank group.

As shown in Table 11, Extract A was proven to have inhibitory effect onAA-induced platelet aggregation in rabbits, which, compared with theblank group, had a significant difference. Compared with the aspiringroup, no significant difference was found in the group A in inhibitingAA-induced platelet aggregation.

TABLE 11 effect of Extract A on AA-induced platelet aggregation inrabbits (x ± s, n = 8) Platelet aggregation Group Dose (mg/kg) rate (%)Blank group  0 9.8 ± 2.33  Aspirin group 60 5.80 ± 1.85** Group A-lowdose 42 7.91 ± 3.12   Group A-high dose 84 5.95 ± 1.54** *P < 0.05, **P< 0.01, compared with the model group.

As shown in Table 12, Extract A was proven to have inhibitory effect oncollagen-induced platelet aggregation in rabbits, which, compared withthe blank group, had a significant difference. Compared with the aspiringroup, no significant difference was found in the group A in inhibitingcollagen-induced platelet aggregation.

TABLE 12 effect of Extract A on collegan-induced platelet aggregation inrabbits (x ± s, n = 8) Platelet aggregation Group Dose (mg/kg) rate (%)Blank group  0 16.6 ± 4.92   Aspirin group 60 6.06 ± 2.07** Group A-lowdose 42 10.21 ± 3.54*   Group A-high dose 84 5.78 ± 0.98** *P < 0.05,**P < 0.01, compared with the model group.

4. Discussion

As shown in the results, administration of Salvia Miltiorrhiza and PanaxNotoginseng extract for 7 consecutive days could take effect ofantimyocardial infarction in ligated rats.

In Group A, the Salvia Miltiorrhiza and Panax Notoginseng extract withborneol was administrated for 7 consecutive days. Obviously, themyocardial infarction rate was less than that in Group B (withoutborneol) and had significantly inhibitory effect on ADP, AA or collageninduced platelet aggregation in rabbits.

The preliminary conclusion showed that addition of borneol mightstrengthen the efficacy of anti-myocardial infarction.

Trial Example 2: Comparative Study on Effect of Acute MyocardialInfarction in Rats Between Two Kinds of CSDPs

1. Animals:

SD male rats, weighing 340˜360 g, were purchased from is BeijingWeitonglihua Experimental Animal Co., Ltd, with certification No.: SCXK(JING) 2007˜0001.

2. Drugs, Reagents and Apparatus

CSMDP was prepared by the method of Preparative Example 15 of CSMDP.

CSDP, used as compared drug, was commercially available in China,prepared by Tianjin Tasly Pharmaceutical Co., Ltd.

Anesthesia was performed by chloral hydrate and triphenyl tetrazoliumchloride (TTC).

Apparatus: MedLab-U/8c bio-signal collecting-processing system,purchased from Nanjin Meiyi Inc.

3. Protocol

Grouping: rats were randomly divided into groups according to the bodyweight: S group (the sham operation group), M group (the model group), Ygroup (the positive group, Metoprolol Tartrate, Lot No. 1201039), Fgroup (the CSMDP group in the present invention) and G group (the CSDPgroup commercially available in China, batch number: 2011L16); 10 ratsin each group.

Modeling and Administrating Method:

After grouping, the animals were administrated intragastrically for 7days, which was seen in Table 13. On 8^(th) day, the rats wereanesthetized by intraperitoneal injection of 10% chloral hydrate (3ml/kg) and fixed on a small wood plate in a supine position. Pins wereinserted under the skin of right forelimb and both hind limbs, which wasconnected with the MedLab-U/8c bio-signal collecting-processing systemto record the ECG of rats. Hair on front wall of left chest was clipped.Oral tracheal cannula was performed and the animal respirator wasconnected at respiratory frequency of 80 breaths/min, tidal volume 3ml/100 g and I:E=1:2. Chest on left front chest lateral side was incisedto cut 3^(rd) rib and the pericardium carefully lifted with forceps totear apart. Left coronary vein trunk pass between the lower edge of leftatrial appendage and pulmonary artery cone was observed in most ofanimals, accompanied with LAD. Medical suture (4-0) was used to ligateLAD and a small amount of myocardial tissue 1˜2 mm from the low edge ofleft atrial appendage inside the interventricular sulcus in the vicinityof left coronary vein trunk. The rats with elevated J point by 0.1 mV inECG and pale LVAW (left ventricular anterior wall) represented thesuccessful modeling. Chest was closed layer by layer. The tracheal tubewas detubated until the respiration was recovered in rats. ECG wasrecorded continuously for 4 hours. Rats were anesthetized, heart takenout, sliced and dyed to calculate myocardial infarction rate (MIR). Theserum was for later use.MIR (%)=wet weight of infarction area/wet weight of whole heart×100%

TABLE 13 Grouping and administration Pre-admin- Concentrate istrationGroup (mg/kg) Dose time S group 110 1 ml/100 g 7 d M group 223 1 ml/100g 7 d Y group 4.5 1 ml/100 g 7 d G group 115 1 ml/100 g 7 d F group 84 1ml/100 g 7 d

4. Results

4.1 Effect on MIR

The results were in Table 14. As shown in Table 14, 7 days afterpre-administration, MIR in M group was significantly higher than that inS group, suggesting the successful modeling. MIR in G group and F groupwere respectively 3.38% and 3.32%, significantly lower than that in Mgroup (5.07%), having a significant difference (p<0.01). It wasindicated that both samples had a certain effect against acutemyocaudial infarction. However, there was no significantly statisticaldifference (p>0.05) in comparison to those in G group and F group.

TABLE 14 effect of CSDP in each group on MIR Average wet Average wetweight of weight of in- Group N whole heart (g) farction area (g) MIR(%) S group  8 0.8254 ± 0.0294 0.0000 ± 0.0000 0.00 ± 0.00 M group 100.8207 ± 0.0447 0.0414 ± 0.0051 5.07 ± 0.75 Y group  9 0.8783 ± 0.05710.0233 ± 0.0038 2.65 ± 0.33* G group 10 0.8493 ± 0.0641 0.0288 ± 0.00523.38 ± 0.49*# F group 10 0.8061 ± 0.0668 0.0268 ± 0.0054 3.32 ± 0.59*#Note: compared with the M group, *p < 0.01; compared with the Y group,#p < 0.01

4.2 Effect on Heart Rate in Rats with Myocardial Infarction

As shown in Table 15, the descending order of heart rate in each groupwas F group, G group, M group, Y group and S group within observationtime and 0˜1 hour after ligation. 1 hour later, the heart rate in eachgroup was decreased. Within observation time, the variation of heartrate in Y group and S group was relatively stable. There was nosignificant difference on heart rate in rats among groups.

TABLE 15 effect of CSDP in each group on heart rate (beat/min) Group N 0s 5 s 10 s 5 min 10 min 30 min 1 h 2 h 3 h 4 h S group 8 390 ± 50 390 ±52 400 ± 51 407 ± 43 401 ± 57 386 ± 69 394 ± 58 417 ± 44 364 ± 42 358 ±36 M group 10 416 ± 83 447 ± 72 436 ± 67 444 ± 43 423 ± 39 423 ± 32 399± 31 361 ± 45 363 ± 46 336 ± 59 Y group 9 377 ± 48 423 ± 39 419 ± 41 424± 29 431 ± 17 413 ± 34 421 ± 47 416 ± 33 380 ± 66 395 ± 52 G group 10431 ± 43 452 ± 21 444 ± 24 445 ± 29 424 ± 27 422 ± 25 397 ± 25 392 ± 40347 ± 39 331 ± 38 F group 10 449 ± 28 498 ± 7  468 ± 34 474 ± 35 466 ±34 426 ± 40 412 ± 40 388 ± 51 377 ± 60 365 ± 56

5. Conclusion

At dose of this study, the medicines in each group were proven to have acertain effect against myocardial infarction in ligature rats oncoronary artery; especially the CSMDP of the present invention (84mg/kg) had MIR of 3.38±0.49%, having a similar efficacy of MIR(3.32±0.59%) with the commercially available CSDP (115 mg/kg).Obviously, the CSMDP at a dose of 84 mg/kg reached the same effect withthe commercially available CSDP at 115 mg/kg. The CSMDP had a betterefficacy than the commercially available CSDP, having the merits of highbioavailability, reduced administration dose and good compliance to thepatients.

What is claimed is:
 1. A Chinese medicine composition consisting of thefollowing materials by weight percentage: 50.0%˜99.9% of SalviaMiltiorrhiza and Panax Notoginseng extract and 0.1%˜50.0% of borneol,wherein the Salvia Miltiorrhiza and Panax Notoginseng extract comprisesthe following ingredients by weight percentage: Danshensu:Salvianolicacid T:protocatechuic aldehyde: Salvianolic acid D:rosmarinicacid:Salvianolic acid B:Salvianolic acid A:Panax Notoginseng SaponinR1:Ginsenoside Rg1:Ginsenoside Re:Ginsenoside Rb1:GinsenosideRd:dihydrotanshinone I:tanshinone I:cryptotanshinone:tanshinoneIIA=(2˜6):(0.5˜2): (1˜3):(0.2˜1):(0.2˜1):(0.5˜2):(0.5˜2):(0.2˜1):(1˜4):(0.1˜0.5):(1˜4):(0.1˜1):(0.01˜0.05):(0.05˜0.1): (0.02˜0.1):(0.1˜0.5). 2.The Chinese medicine composition according to claim 1, wherein saidChinese medicine composition consists of the following materials byweight percentage: 75.0%˜99.9% of Salvia Miltiorrhiza and PanaxNotoginseng extract and 0.1%˜25.0% of borneol.
 3. The Chinese medicinecomposition according to claim 1, wherein said traditional Chinesemedicine composition is composed of the following materials by weightpercentage: 90.0%˜99.9% of Salvia Miltiorrhiza and Panax Notoginsengextract and 0.1%˜10.0% of borneol.
 4. The Chinese medicine compositionaccording to claim 1, wherein the Salvia Miltiorrhiza and PanaxNotoginseng extract comprises the following ingredients by weight parts:Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acidD:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1: Ginsenoside Rg1:Ginsenoside Re:GinsenosideRb1:Ginsenoside Rd:dihydrotanshinone I:tanshinoneI:cryptotanshinone:tanshinone IIA=(3˜4):(0.9˜1.2):(1.4˜2.0):(0.5˜0.7):(0.5˜0.9):(1˜1.6):(0.7˜1.2):(0.5˜0.9):(1.8˜2.8):(0.2˜0.4):(1.7˜2.2):(0.2˜0.6):(0.03˜0.04):(0.07˜0.08):(0.05˜0.06):(0.26˜0.28).
 5. The Chinese medicinecomposition according to claim 4, wherein the Salvia Miltiorrhiza andPanax Notoginseng extract comprises the following ingredients by weightparts: Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolicacid D:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:PanaxNotoginseng Saponin R1: Ginsenoside Rg1:Ginsenoside Re:GinsenosideRb1:Ginsenoside Rd:dihydrotanshinone I:tanshinone I: cryptotanshinone:tanshinoneIIA=3.6:1.1:1.7:0.6:0.7:1.3:0.9:0.7:2.4:0.3:1.8:0.4:0.03:0.07:0.06:0.27.6. The Chinese medicine composition according to claim 1, wherein theSalvia Miltiorrhiza and Panax Notoginseng extract is prepared with thefollowing crude medicine by weight parts: Salvia Miltiorrhiza 75˜90parts and Panax Notoginseng 10˜25 parts.
 7. The Chinese medicinecomposition according to claim 6, wherein the Salvia Miltiorrhiza andPanax Notoginseng extract is prepared with the following crude medicineby weight parts: Salvia Miltiorrhiza 82˜84 parts, Panax Notoginseng16˜17 parts.
 8. A pharmaceutical preparation comprising the Chinesemedicine composition according to claim 1 and pharmaceuticallyacceptable carriers.
 9. The pharmaceutical preparation according toclaim 8, wherein said pharmaceutical preparation is in a dosage form ofdrop pill or micro drop pill, wherein said micro drop pill is preparedwith the Chinese medicine composition and drop pill matrix in a ratio of1:5˜5:1 by weight.
 10. The pharmaceutical preparation according to claim9, wherein said pharmaceutical preparation is a compound Salvia microdrop pill.
 11. The Chinese medicine composition according to claim 4,wherein said traditional Chinese medicine composition is composed of thefollowing materials by weight percentage: 90.0%˜9.9% of SalviaMiltiorrhiza and Panax Notoginseng extract and 0.1%˜10.0% of borneol.12. The Chinese medicine composition according to claim 4, wherein theSalvia Miltiorrhiza and Panax Notoginseng extract is prepared with thefollowing crude medicine by weight parts: Salvia Miltiorrhiza 75-90parts and Panax Notoginseng 10-25 parts.
 13. A pharmaceuticalpreparation comprising the Chinese medicine composition according toclaim 4 and pharmaceutically acceptable carriers.